US20170340460A1 - Systems and methods for making encapsulated hourglass shaped stents - Google Patents
Systems and methods for making encapsulated hourglass shaped stents Download PDFInfo
- Publication number
- US20170340460A1 US20170340460A1 US15/608,948 US201715608948A US2017340460A1 US 20170340460 A1 US20170340460 A1 US 20170340460A1 US 201715608948 A US201715608948 A US 201715608948A US 2017340460 A1 US2017340460 A1 US 2017340460A1
- Authority
- US
- United States
- Prior art keywords
- stent
- mandrel
- graft
- biocompatible material
- assembly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/844—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents folded prior to deployment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0041—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using additional screws, bolts, dowels or rivets, e.g. connecting screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0058—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements soldered or brazed or welded
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/001—Figure-8-shaped, e.g. hourglass-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0067—Three-dimensional shapes conical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0073—Quadric-shaped
- A61F2230/0078—Quadric-shaped hyperboloidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/002—Designing or making customized prostheses
- A61F2240/004—Using a positive or negative model, e.g. moulds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
Definitions
- This application relates to systems and methods for the manufacture of hourglass or “diabolo” shaped encapsulated stents for treating congestive heart failure and other disorders treated with encapsulated hourglass shaped stents.
- Heart failure is the physiological state in which cardiac output is insufficient to meet the needs of the body and the lungs.
- Congestive Heart Failure occurs when cardiac output is relatively low due to reduced contractility or heart muscle thickening or stiffness.
- CHF Congestive Heart Failure
- CHF is associated with neurohormonal activation and alterations in autonomic control. Although these compensatory neurohormonal mechanisms provide valuable support for the heart under normal physiological circumstances, they also have a fundamental role in the development and subsequent progression of CHF.
- one of the body's main compensatory mechanisms for reduced blood flow in CHF is to increase the amount of salt and water retained by the kidneys. Retaining salt and water, instead of excreting it into the urine, increases the volume of blood in the bloodstream and helps to maintain blood pressure.
- the larger volume of blood also stretches the heart muscle, enlarging the heart chambers, particularly the ventricles. At a certain amount of stretching, the hearts contractions become weakened, and the heart failure worsens.
- Another compensatory mechanism is vasoconstriction of the arterial system. This mechanism, like salt and water retention, raises the blood pressure to help maintain adequate perfusion.
- EF ejection fraction
- CHF Heart Failure with reduced Ejection Fraction (HFrEF) or Heart Failure with preserved Ejection Fraction (HFpEF).
- HFrEF Heart Failure with reduced Ejection Fraction
- HFpEF Heart Failure with preserved Ejection Fraction
- stroke volume the blood ejected out of the left ventricle
- End Diastolic Volume the maximum volume remaining in the left ventricle at the end of diastole or relaxation phase.
- End Diastolic Volume A normal ejection fraction is greater than 50%.
- HFrEF has a decreased ejection fraction of less than 40%.
- a patient with HFrEF may usually have a larger left ventricle because of a phenomenon called cardiac remodeling that occurs secondarily to the higher ventricular pressures.
- HFpEF HFpEF
- the heart In HFpEF, the heart generally contracts normally, with a normal ejection fraction, but is stiffer, or less compliant, than a healthy heart would be when relaxing and filling with blood. This stiffness may impede blood from filling the heart, and produce backup into the lungs, which may result in pulmonary venous hypertension and lung edema.
- HFpEF is more common in patients older than 75 years, especially in women with high blood pressure.
- assist devices such as mechanical pumps have been used to reduce the load on the heart by performing all or part of the pumping function normally done by the heart.
- Chronic left ventricular assist devices (LVAD), and cardiac transplantation often are used as measures of last resort.
- LVAD left ventricular assist devices
- Such assist devices are typically intended to improve the pumping capacity of the heart, to increase cardiac output to levels compatible with normal life, and to sustain the patient until a donor heart for transplantation becomes available.
- Such mechanical devices enable propulsion of significant volumes of blood (liters/min), but are limited by a need for a power supply, relatively large pumps, and the risk of hemolysis, thrombus formation, and infection.
- surgical approaches such as dynamic cardiomyoplasty or the Batista partial left ventriculectomy may also be used in severe cases. However these approaches are highly invasive and have the general risks associated with highly invasive surgical procedures.
- U.S. Pat. No. 6,468,303 to Amplatz et al. describes a collapsible medical device and associated method for shunting selected organs and vessels.
- the device may be suitable to shunt a septal defect of a patient's heart, for example, by creating a shunt in the atrial septum of a neonate with hypoplastic left heart syndrome (HLHS).
- HLHS hypoplastic left heart syndrome
- Amplatz describes that increasing mixing of pulmonary and systemic venous blood improves oxygen saturation.
- the shunting passage can later be closed by an occluding device.
- Amplatz is silent on the treatment of CHF or the reduction of left atrial pressure, and is also silent on means for regulating the rate of blood flow through the device.
- U.S. Pat. No. 8,070,708 to Rottenberg describes a method and device for controlling in-vivo pressure in the body, and in particular, the heart.
- the device described in Rottenberg involves a shunt to be positioned between two or more lumens in the body to permit fluid to flow between the two lumens.
- the Rottenberg patent further describes that an adjustable regulation mechanism may be configured to cover an opening of the shunt to regulate flow between the two lumens.
- the shunt is configured such that the flow permitted is related to a pressure difference between the two lumens.
- the adjustable regulation mechanism may be remotely activated.
- the Rottenberg patent describes that the device described may be used to treat CHF by controlling pressure difference between the left atrium and the right atrium. While Rottenberg describes a mechanism for treating CHF by controlling the flow between the left atrium and the right atrium, it does not describe the encapsulation of an hourglass shaped stent.
- U.S. Patent Publication No. 2005/0165344 to Dobak, III describes an apparatus for treating heart failure that includes a conduit positioned in a hole in the atrial septum of the heart, to allow flow from the left atrium into the right atrium.
- Dobak describes that the shunting of blood will reduce left atrial pressures, thereby preventing pulmonary edema and progressive left ventricular dysfunction, and reducing LVEDP.
- the conduit may include a self-expandable tube with retention struts, such as metallic arms that exert a slight force on the atrial septum on both sides and pinch or clamp the valve to the septum, and a one-way valve member, such as a tilting disk, bileaflet design, or a flap valve formed of fixed animal pericardial tissue.
- a valved design may not be optimal due to a risk of blood stasis and thrombus formation on the valve, and that valves can also damage blood components due to turbulent flow effects. Dobak does not provide any specific guidance on how to avoid such problems.
- Nitzan describes a device for regulating blood pressure between a patient's left atrium and right atrium which comprises an hourglass-shaped stent having a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum.
- Nitzan describes that the hourglass shaped stent is also encapsulated with a biocompatible material. While Nitzan describes a method for the manufacture of an hourglass shaped stent for the treatment of CHF, Nitzan is silent on the method of encapsulating the stent.
- McCrea describes methods for encapsulating an endoluminal stent fabricated from a shape memory alloy. The Method described by McCrea involves an endoluminal stent encapsulated in an ePTFE covering which circumferentially covers both the luminal and abluminal walls along at least a portion of the longitudinal extent of the endoluminal stent. McCrea further describes applying pressure to the stent-graft assembly and heating the assembly to complete the encapsulation. While McCrea describes an encapsulated endoluminal stent, it does not describe the encapsulation of an hourglass shaped stent for the treatment of CHF.
- the present invention overcomes the drawbacks of previously-known systems and methods by providing systems and methods for making encapsulated hourglass shaped stents for treating CHF and other conditions benefited by encapsulated hourglass shaped stents such as pulmonary hypertension.
- the hourglass or “diabolo” shaped stents are configured to be encapsulated using a mandrel assembly.
- a method for making an encapsulated stent-graft may involve, providing a mandrel having a first conical region with a first apex and a second conical region with a second apex, placing an expandable stent having an hourglass shape in an expanded form on the mandrel so that a first flared end region of the expandable stent conforms to the first conical region and a second flared end region of the expandable stent conforms to the second conical region, associating a biocompatible material with the expandable stent to form a stent-graft assembly, and compressing the stent-graft assembly against the mandrel to form the encapsulated stent-graft.
- the first conical region and the second conical region may be aligned so that the first and second apexes contact one another.
- the biocompatible material may have first and second ends and associating the biocompatible material with the expandable stent involves placing the biocompatible material within a lumen of the expandable stent.
- the method may further include placing a second biocompatible material over the expandable stent.
- Compressing the stent-graft assembly may involve winding a layer of tape over the biocompatible material to compress the stent-graft assembly against the mandrel.
- the expandable stent may include through-wall openings, and the method may further involve heating the stent-graft assembly to cause the biocompatible material and the second biocompatible material to bond to one another through the through-wall openings.
- Heating the stent-graft assembly may cause the biocompatible material and the second biocompatible material to become sintered together to form a monolithic layer of biocompatible material.
- the method may further involve applying a layer of Fluorinated Ethylene Propylene (FEP) to biocompatible material or second biocompatible material.
- FEP Fluorinated Ethylene Propylene
- the biocompatible material may be pre-formed.
- the method may further involve manipulating the encapsulated stent-graft to a compressed shape and loading the encapsulated stent-graft into a delivery sheath.
- a first end diameter of the expandable stent may be different in size from a second end diameter.
- the mandrel may have a neck region disposed between a first conical region and a second conical region and the mandrel may be configured to be removably uncoupled at the neck region into a first half having at least the first conical region and a second half having at least the second conical region.
- a method for making an encapsulated stent-graft may involve providing a mandrel assembly having an asymmetric shape, providing an expandable stent in an expanded form, coupling a biocompatible material to the expandable stent to form a stent-graft assembly, and compressing the stent-graft assembly on the mandrel assembly to form the encapsulated stent-graft.
- the expandable stent may be configured to conform to the asymmetric shape formed by the mandrel assembly.
- the expandable stent and the biocompatible material may be coupled on the mandrel assembly or before placement on the mandrel assembly.
- the method may further involve coupling a second biocompatible material to an opposing surface of the expandable stent to form the stent-graft assembly.
- the second biocompatible material may be formed of a same or different material as the biocompatible material.
- the mandrel assembly may include a first mandrel and a second mandrel, and the method may further involve, positioning the first mandrel within the first end of the expandable stent such that a portion of the second biocompatible material is positioned between the first mandrel and the expandable stent, and positioning the second mandrel within the second end of the expandable stent such that a portion of the second biocompatible material is positioned between the second mandrel and the expandable stent.
- the biocompatible material may be a pre-formed biocompatible graft layer having the expandable stent. The pre-formed biocompatible graft layer may engage the expandable stent on the mandrel assembly.
- a method for making an encapsulated stent-graft may involve providing an asymmetrical stent, placing a first biocompatible material over the asymmetrical stent, providing a second biocompatible material for placement within the asymmetrical stent, inserting a balloon catheter having an inflatable balloon within the asymmetrical stent in a deflated state such that the second biocompatible material is between the asymmetrical stent and the inflatable balloon, and inflating the inflatable balloon to an inflated state conforming to the shape of the asymmetrical stent, thereby causing the second biocompatible material to engage with the asymmetrical stent to form the encapsulated stent-graft.
- the method may further involve controlling the pressure within the balloon to achieve a desired adhesion between the first biocompatible material and the second biocompatible material.
- the method may further involve controlling the pressure within the balloon to achieve a desired inter-nodal-distance of the graft material.
- the second biocompatible material may be placed within the asymmetrical stent prior to inserting the balloon catheter within the asymmetrical stent.
- the second biocompatible material may be disposed on the inflatable balloon, and inflating the inflatable balloon may cause the second biocompatible material disposed on the inflatable balloon to contact and inner surface of the asymmetrical stent thereby engaging the second biocompatible material with the asymmetrical stent.
- a method for making an encapsulated stent-graft may involve providing a funnel having a large end and a small end, placing an asymmetric stent with a first end, a second end, an exterior surface and an interior surface within the large end of the funnel, placing a biocompatible tube over the small end of the funnel, the biocompatible tube having a stent receiving portion and a remaining portion, advancing the asymmetric stent through the funnel and out the small end of the funnel, thereby depositing the asymmetric stent into the biocompatible tube such that the stent is positioned within the stent receiving portion of the biocompatible tube, thereby engaging an exterior surface of the asymmetric stent with the biocompatible tube, pulling the remaining portion of the biocompatible tube through the first end of the asymmetric stent and out the second end, introducing a first mandrel having a shape similar to the first side of the asymmetric stent into the first side of asymmetric stent thereby engaging the interior
- an hourglass shaped mandrel assembly for making an encapsulated stent-graft may involve a first portion having at least a first conical region having a flared end with a first diameter and an apex end with a second diameter, a second portion having at least a second conical region having a flared end with third diameter and an apex end with a fourth diameter, and a tapered region coupled to the flared end of the first portion and extending away from the flared end of the first portion.
- the tapered region may have a flared end with a fifth diameter and a tapered end with a sixth diameter such that the fifth diameter is equal to the first diameter and the sixth diameter is smaller than the fifth diameter.
- the first conical region of the first portion and the second conical region of the second portion may be aligned so that apexes of the first portion and second portion are contacting one another.
- the hourglass shaped mandrel assembly may further include a neck region positioned between the apex end of the first portion and the apex end of the second portion such that the neck region is affixed to at least the first portion or the second portion.
- the first portion and the second portion may be removably coupled at the apex end of the first portion and the apex end of the second portion.
- the hourglass shaped mandrel may be configured to expand radially.
- FIG. 1 is side view of hourglass shaped stent constructed in accordance with the methods of the present invention.
- FIG. 2 is a cross-section view of hourglass shaped stent encapsulated with first and second graft layers.
- FIG. 3 is a partially exploded side view of assembly apparatus for manufacturing hourglass stent-graft assembly in accordance with the methods of the present invention.
- FIG. 4 is a side view of hourglass shaped mandrel assembly section of assembly apparatus for manufacturing hourglass shaped stent-graft assembly in accordance with the methods of the present invention.
- FIG. 5 is a side view of assembly apparatus engaged with first graft tube at the tapered region.
- FIG. 6 is a side view of assembly apparatus engaged with first graft tube over hourglass shaped mandrel assembly section.
- FIG. 7 is a side view of first graft layer disposed over hourglass shaped mandrel assembly section of assembly apparatus.
- FIGS. 8A-8C are side views of assembly apparatus engaged with first graft layer and hourglass shaped stent.
- FIG. 9 is a side view of assembly apparatus engaged with second graft tube at the tapered region.
- FIG. 10 is a side view of assembly apparatus engaged with second graft tube over hourglass shaped mandrel assembly section of assembly apparatus.
- FIG. 11 is a side view of stent-graft disposed over hourglass shaped mandrel assembly section.
- FIGS. 12A-12D are side views sequentially illustrating an encapsulation technique involving a male and female mandrel.
- FIGS. 13A-13E are side views sequentially illustrating an encapsulation technique involving pre-shaped grafts and a male and female mandrel.
- FIGS. 14A-14D are side views sequentially illustrating an encapsulation technique involving an inflatable balloon.
- FIGS. 15A-15F are side views sequentially illustrating an encapsulation technique involving a funnel and a male and female mandrel.
- Embodiments of the present invention are directed to systems and methods for the manufacture of hourglass or “diabolo” shaped stents encapsulated with biocompatible material for treating subjects suffering from congestive heart failure (CHF) or alternatively pulmonary hypertension.
- the hourglass or “diabolo” shaped stents are configured to be encapsulated using an hourglass shaped mandrel assembly having a dilation portion and two conical regions that may be removably coupled.
- the hourglass shaped stents may be specifically configured to be lodged securely in the atrial septum, preferably the fossa ovalis, to allow blood flow from the left atrium to the right when blood pressure in the left atrium exceeds that on the right atrium.
- the resulting encapsulated stents are particularly useful for the purpose of inter-atrial shunting as they provide long-term patency and prevent tissue ingrowth within the lumen of the encapsulated stent.
- the systems and methods described herein may also be applicable to other conditions benefited from an encapsulated hourglass shaped stent such as pulmonary hypertension wherein the encapsulated hourglass shaped stent is used as a right-to-left shunt.
- Stent 110 is illustrated.
- Stent 110 is hourglass or “diabolo” shaped and may be radially self-expandable.
- stent 110 may be expandable but not self-expandable.
- stent 110 may be balloon expandable.
- Stent 110 has three general regions: first flared end region 102 , second end flared region 106 , and neck region 104 disposed between the first and second flared end regions.
- First flared end region 102 has first end region diameter D 1
- second flared end region 106 has second end region diameter D 2
- neck region 104 has neck diameter D 3 . As shown in FIG.
- neck region 104 of stent 110 is significantly narrower than flared end regions 102 and 106 .
- stent 110 may be asymmetric.
- stent 110 may be asymmetric to take advantage of the natural features of the atrial septum of the heart as well as the left and right atrium cavities.
- hourglass shaped stent 110 may be symmetric with the first end region diameter D 1 being equal to the second end region diameter D 2 .
- First flared end region 102 and second flared end region 106 also may have either straight or curved profiles or both.
- strut 111 has a straight profile and strut 108 has a curved profile.
- first flared end region 102 and second flared end region 106 may assume any angular position consistent with the hour-glass configuration.
- Stent 110 is preferably comprised of a self-expanding material having superelastic properties.
- a shape-memory metal such as nickel titanium (NiTi), also known as NITINOL may be used.
- NiTi nickel titanium
- NITINOL nickel titanium
- Other suitable materials known in the art of deformable stents for percutaneous implantation may alternatively be used such as other shape memory alloys, self-expanding materials, superelastic materials, polymers, and the like.
- the tube may be laser-cut to define a plurality of struts and connecting members. For example, as illustrated in FIG. 1 , the tube may be laser-cut to define a plurality of sinusoidal rings connected by longitudinally extending struts.
- Struts 108 and 111 and sinusoidal rings 112 - 116 illustrated in FIG. 1 may be laser cut to form an integral piece of unitary construction.
- struts 111 and sinusoidal rings 112 - 116 may be separately defined to form different pieces of shape-memory metal and subsequently coupled together to form stent 110 .
- the stent may also be electropolished to reduce thrombogenicity.
- Stent 110 may be expanded on a mandrel to define first end region 102 , second end region 106 , and neck region 104 .
- the expanded stent then may be heated to set the shape of stent 110 .
- the stent may be expanded on a mandrel in accordance with the teachings of U.S. Pat. No. 9,034,034 to Nitzan, incorporated herein.
- stent 110 is formed from a tube of NITINOL, shaped using a shape mandrel, and placed into an oven for 11 minutes at 530° C. to set the shape.
- the mandrel disclosed in FIGS. 3-4 may be configured as a shaping mandrel to set the shape of stent 110 or, alternatively, a different mandrel may be used as the shaping mandrel.
- Biocompatible material may be expanded polytetrafluoroethylene (ePTFE), silicone, polycarbonate urethane, DACRON (polyethylene terephthalate), Ultra High Molecular Weight Polyethylene (UHMWPE), or polyurethane, or of a natural material such as pericardial tissue, e.g., from an equine, bovine, or porcine source or human tissue such as human placenta or other human tissues.
- ePTFE expanded polytetrafluoroethylene
- silicone silicone
- polycarbonate urethane polycarbonate urethane
- DACRON polyethylene terephthalate
- UHMWPE Ultra High Molecular Weight Polyethylene
- the biocompatible material is preferably smooth so as to inhibit thrombus formation, and optionally may be impregnated with carbon so as to promote tissue ingrowth.
- the biocompatible material may form a mesh-like structure.
- the biocompatible material may be pre-shaped using a dedicated pre-shaping mandrel and heat treatment to simplify the mounting of the biocompatible material on an encapsulation mandrel, as discussed in detail below. Pre-shaping the biocompatible material has been shown to simplify the handling and mounting of the biocompatible material on the mandrel, thereby reducing stretching and the risk for tears in the biocompatible material and may be especially beneficial for encapsulating asymmetrical stents. Portions of stent 110 such as first flared end region 102 may not be covered with the biocompatible material.
- the stent is positioned between a first and second layer of graft material by covering an inner surface of stent 121 with first graft layer 170 , and covering the outer surface of stent 123 with second graft layer 190 .
- First graft layer 170 and second graft layer 190 each may have a first end and a second end and may have lengths that are about equal. Alternatively, first graft layer 170 and second graft layer 190 may have different lengths.
- Stent 110 may have a length that is shorter than the length of first graft layer 170 and second graft layer 190 .
- stent 110 may have a length that is longer than the length of first graft layer 170 and/or second graft layer 190 .
- the graft layers may be securely bonded together to form a monolithic layer of biocompatible material.
- first and second graft tubes may be sintered together to form a strong, smooth, substantially continuous coating that covers the inner and outer surfaces of the stent. Portions of the coating then may be removed as desired from selected portions of the stent using laser-cutting or mechanical cutting, for example.
- stent 110 is encapsulated with ePTFE.
- ePTFE materials have a characteristic microstructure consisting of nodes and fibrils, with the fibrils orientation being substantially parallel to the axis of longitudinal expansion.
- Expanded polytetrafluoroethylene materials are made by ram extruding a compressed billet of particulate polytetrafluoroethylene and extrusion lubricant through an extrusion die to form sheet or tubular extrudates.
- the extrudate is then longitudinally expanded to form the node-fibril microstructure and heated to a temperature at or above the crystalline melt point of polytetrafluoroethylene, i.e., 327° C., for a period of time sufficient to sinter the ePTFE material.
- Heating may take place in a vacuum chamber to prevent oxidation of the stent.
- heating may take place in a nitrogen rich environment.
- a furnace may be used to heat the stent-graft assembly.
- the mandrel upon which the stent-graft assembly rests may be a heat source used to heat the stent-graft assembly.
- FIGS. 3-11 generally illustrate one method of making stent-graft assembly 120 , as depicted in FIGS. 1-2 .
- FIG. 3 is a partially exploded view of assembly apparatus 130 .
- Assembly apparatus 130 may comprise tapered dilation mandrel 131 , stent retaining mandrel 134 and stent enclosing mandrel 138 .
- Tapered dilation mandrel 131 comprises first end 132 having a taper diameter and second end 133 wherein the diameter of second end 133 is greater than the taper diameter.
- assembly apparatus 130 may comprise stent retaining mandrel 134 and stent enclosing mandrel 138 .
- Stent retaining mandrel 134 may be permanently affixed to second end 133 of tapered dilation mandrel 131 or alternatively may be removably coupled to tapered dilation mandrel.
- stent retaining mandrel 134 may be screwed into tapered dilation mandrel 131 using a screw extending from stent retaining mandrel 134 and a threaded insert embedded into tapered dilation mandrel 131 .
- couplings are interchangeable and may be any of a wide variety of suitable couplings.
- Stent retaining mandrel 134 may comprise a conical region defined by large diameter end 135 and an apex end 136 .
- Large diameter end 135 may be equal in diameter with second end 133 of tapered dilation mandrel 131 , and larger in diameter than apex end 136 .
- stent retaining mandrel 134 may alternatively be other shapes including non-conical shapes.
- Stent retaining mandrel 134 may optionally incorporate neck region 137 .
- Neck region 137 may extend from apex end 136 , as shown in FIG. 3 , and may have the same diameter as apex end 136 .
- neck region 137 may extend from stent enclosing mandrel 138 .
- Stent enclosing mandrel 138 is removably coupled to stent retaining mandrel 134 .
- stent enclosing mandrel 138 may be screwed into stent retaining mandrel 134 using screw 139 extending from stent enclosing mandrel 138 and threaded insert 140 embedded into stent retaining mandrel 134 .
- screw 139 may extend from stent retaining mandrel 134 and threaded insert may be embedded into stent enclosing mandrel 138 .
- stent retaining mandrel 134 may be a female mandrel having a receiving portion and stent enclosing mandrel 138 may be a male mandrel having a protruding portion.
- stent retaining mandrel 134 may be a male mandrel having a protruding portion and stent enclosing mandrel 138 may be a female mandrel having a receiving portion.
- Stent enclosing mandrel 138 may comprise a conical region defined by large diameter end 142 and an apex end 141 , wherein large diameter end 142 is larger in diameter than apex end 141 . It is understood that stent enclosing mandrel 138 alternatively take other shapes including non-conical shapes. Stent enclosing mandrel 138 may be permanently affixed to handle segment 144 at large diameter end 142 . Alternatively, stent enclosing mandrel 138 may be removably coupled to handle segment 144 .
- handle segment 144 may be removed and replaced with a taper mandrel segment similar to taper dilation mandrel 131 , as shown in FIG. 8C .
- Hourglass shaped mandrel assembly 143 is configured such that the conical region of stent retaining mandrel 134 is oriented toward the conical region of stent enclosing mandrel 138 , wherein apex end 136 of stent retaining mandrel 138 having extending neck region 137 is in contact with apex end 141 of stent enclosing mandrel 138 .
- Neck region 137 is configured to conform to the diameter of apex end 136 of stent retaining mandrel 138 and apex end 141 of stent enclosing mandrel 138 , whether or not apex end 141 and apex end 136 are equal in diameter. Neck region 137 may vary in diameter or may be eliminated entirely.
- hourglass shaped mandrel assembly 143 and specifically the size of the conical regions of stent retaining mandrel 134 and stent enclosing mandrel 138 preferably correspond to the size and shape of flared end region 102 , neck region 104 and second flared end region 106 of stent 110 .
- Hourglass shaped mandrel assembly 143 may be asymmetrical such that diameter D 4 of large diameter end 135 is different than diameter D 5 of large diameter end 142 .
- diameter D 4 and diameter D 5 may be the same.
- angle ⁇ 1 and angle ⁇ 2 may be different, resulting in an asymmetrical mandrel, or may be the same.
- Angle ⁇ 1 and angle ⁇ 2 also may vary along the length of hourglass shaped mandrel assembly 143 to better conform to stent 110 . While neck diameter D 6 may vary at different points along neck region 137 , diameter at neck region 137 is at all times smaller than diameter D 4 and D 5 .
- FIGS. 5-7 represents sequential views of first graft tube 122 being loaded onto the tapered dilation mandrel 131 and being concentrically engaged about hourglass shaped assembly 143 in an exemplary sequence. Engagement of first graft tube 122 over tapered dilation mandrel 131 may be facilitated by forming tabs on first end 153 of first graft tube 122 by cutting longitudinal slits (not shown) along diametrically opposing sides of the graft tube. The tabs can then be used to retain first graft tube 122 while axial force 150 is applied to assembly apparatus 130 .
- the tabs may be used to manually pull first graft tube 122 over tapered dilation mandrel 131 and hourglass shaped mandrel assembly 143 .
- Cutting crevice 151 and 152 may be incorporated into stent retaining mandrel 134 and stent enclosing mandrel 138 to provide a guiding indentation for a cutting element to cut first graft tube 122 and second graft tube 124 .
- first graft tube 122 may be engaged with tapered dilatation mandrel 131 by applying an axial force 150 to assembly apparatus 130 which causes the tapered dilatation mandrel to pass into and through lumen 154 of first graft tube 122 .
- first graft tube 122 passes over second end 133 of tapered dilatation mandrel 131 , the inner diameter of first graft first 122 is expanded radially to that of the outer diameter of second end 133 of tapered dilation mandrel 131 .
- first graft tube 122 undergoes radial recoil so that the inner diameter of first graft tube 122 reduces until it's met with resistance from hourglass shaped mandrel 143 .
- first graft tube 122 has radially recoiled onto hourglass shaped mandrel assembly 143 as well as into cutting crevices 151 and 152 .
- FIGS. 6 and 7 illustrate the steps for separating first graft tube 122 and depositing graft layer 170 upon hourglass shaped mandrel 143 .
- Cutting blades 160 and 161 may be used to make circumferential cuts in first graft tube 122 near the large diameter ends of stent retaining mandrel 134 and stent enclosing mandrel 138 .
- cutting blades may make circumferential cuts at the position of cutting crevices 151 and 152 .
- Cutting crevices 151 and 152 are positioned at a length longer than the length of stent 110 to account for recoil of graft material after being cut.
- first graft layer 170 is deposited onto stent 110 .
- first end 153 of first graft tube 122 having tabs at the end may serve as one end of first graft layer 170 .
- First graft layer 170 has a length longer than stent 110 .
- first graft layer 170 extends beyond opposing ends of stent 110 .
- first graft layer 170 remains on the assembly apparatus and covers hourglass shaped mandrel assembly 143 .
- Tape may be applied to first graft layer 170 to secure graft layer 170 to stent retaining mandrel 134 .
- an optional step involves applying a layer of Fluorinated Ethylene Propylene (FEP), or any other adhesive material, to first graft layer 170 for improving adhesion during encapsulation process.
- FEP Fluorinated Ethylene Propylene
- stent 110 may be loaded onto hourglass shaped mandrel assembly 143 .
- One method for loading stent 110 onto hourglass shaped mandrel assembly 143 is to uncouple stent retaining mandrel 134 and stent enclosing mandrel 138 .
- first graft layer 170 in contact with stent retaining mandrel 134 and neck region 137 will remain supported by the stent retaining mandrel 134 but the portion that was in contact with stent enclosing mandrel 138 will become unsupported beyond neck region 137 .
- stent 110 may be loaded onto stent retaining mandrel 134 over first graft layer.
- first graft layer 170 may be manipulated in shape and guided through an interior opening of neck region 104 and through an interior of second flared end region 106 .
- first end 153 of first graft tube 122 is used as the end of first graft layer 170
- the tabs on first end 153 of first graft tube 122 described above may be used to help guide first graft layer 170 through stent 110 .
- Stent 110 is engaged about the stent retaining mandrel 134 by concentrically positioning the stent 110 over first graft layer 170 and stent retaining mandrel 134 .
- first flared end region 102 , and neck region 104 of stent 110 engage with stent retaining mandrel 134 while second flared end region 106 does not.
- Stent retaining mandrel 134 and first graft layer 170 are configured to have a combined diameter which is less than the inner diameters of first flared end region 102 and neck region 104 of stent 110 , allowing stent to slide onto stent retaining mandrel 134 .
- first graft layer 170 may be manually manipulated to avoid being damaged and prevent the occurrence of any wrinkles during recoupling of stent enclosing mandrel 138 .
- first graft layer 170 may be held by the tabs described above while the stent enclosing mandrel is recoupled to the stent retaining mandrel.
- first graft layer was taped to stent retaining mandrel 134 , the tape may be removed after recoupling.
- stent enclosing mandrel 138 is coupled to stent retaining mandrel 134 , stent enclosing mandrel 138 engages both first graft layer 170 and second flared end region 106 of stent 110 , locking stent 110 into position between large diameter end 135 and large diameter end 142 .
- Stent enclosing mandrel 138 and first graft layer 170 are configured to have a combined outside diameter which is less than the inner diameter of second flared end region 106 of stent 110 , allowing stent 110 to slide into position on stent enclosing mandrel 138 .
- an optional step involves applying a layer of FEP, or any other adhesive material, to first graft layer 170 and stent 110 for improving adhesion during encapsulation process.
- first graft layer 170 may be deposited onto assembly apparatus 130 in different ways.
- first graft layer 170 may not be separated from first graft tube 122 until after stent 110 has been loaded onto assembly apparatus 130 .
- first end 153 of first graft tube 122 is positioned near large diameter end 142 of stent enclosing mandrel 138 and first graft tube 122 undergoes radial recoil so that the inner diameter of first graft tube 122 reduces until it is met with resistance from hourglass shaped mandrel 143 , as shown in FIG.
- stent retaining mandrel 138 may be uncoupled from stent enclosing mandrel 134 .
- the portion of the first graft tube extending beyond neck region 137 will become unsupported after stent enclosing mandrel 138 has been uncoupled.
- the unsupported region of first graft tube 122 may then be manipulated in shape and guided through an interior opening of neck region 104 and through an interior of second flared end region 106 as described above.
- cuts may be made using cutting blades 160 and 161 to separate first graft tube 122 from first graft layer 170 .
- first graft layer 170 may be deposited onto hourglass shaped mandrel 143 using an electrospinning process.
- Electrospinning is a process in which polymers are electrospun into ultrafine fibers which are deposited upon a target surface. The electrospinning process involves applying an electric force to draw fibers out of polymer solutions or polymer melts.
- ultrafine fibers such as ePTFE fibers may be deposited onto hourglass shaped mandrel 143 to form first graft layer 170 .
- Assembly apparatus may be continuously rotated about its longitudinal axis to evenly apply the ePTFE fibers.
- stent retaining mandrel 134 and stent enclosing mandrel 138 may be coupled together during the electrospinning process.
- stent retaining mandrel 134 and stent enclosing mandrel 138 may be uncoupled and the conical region of stent retaining mandrel 134 including neck region 137 may be subjected to the electrospinning process separate from the conical region of stent enclosing mandrel 138 .
- first graft layer 170 may similarly be deposited using electrospinning.
- assembly apparatus 130 may be configured such that first graft tube 122 and second graft tube 124 may be loaded onto assembly apparatus 130 from the side closest to stent enclosing mandrel 138 .
- stent enclosing mandrel 138 may be removably coupled to handle segment 144 .
- stent enclosing mandrel 138 may be uncoupled from handle segment 144 and tapered dilation mandrel 131 ′ may be coupled to stent enclosing mandrel 138 instead.
- Tapered dilation mandrel 131 ′ has first end 132 ′ and second end 133 ′ wherein the diameter of second end 133 ′ is greater than the diameter of first end 132 ′ and the diameter of second end 133 ′ is equal to the diameter of large diameter end 142 of stent enclosing mandrel 138 .
- large diameter end 135 may also perform as handle segment 144 ′ for pushing.
- an axial force 165 may be applied to assembly apparatus 130 to cause tapered dilatation mandrel 131 ′ having first end 132 ′ to pass into and through the lumen of the first graft tube 122 .
- axial force 165 may be applied to assembly apparatus 130 to guide assembly apparatus 130 , and specifically first end 132 ′, into stent 110 which is configured to expand as tapered dilatation mandrel 131 ′ is pushed into stent 110 .
- Axial force 165 may be applied by using handle segment 144 ′ to push assembly apparatus 130 .
- first end region diameter D 1 , second end region diameter D 2 , and neck diameter D 3 of stent 110 may be expanded to a diameter equal to or larger than large diameter end 142 of stent enclosing mandrel 138 , thus permitting stent 110 to traverse large diameter end 142 .
- stent 110 As stent 110 exhibiting spring tension is passed over hourglass shaped mandrel assembly 143 , it encounters no resistance to radial recoil and thus radially recoils into position over first graft layer 170 and between large diameter end 135 and large diameter end 142 .
- stent 110 may be expanded to a slightly larger diameter than second diameter end 142 by applying a radially expansive force on stent 110 using an external expansion tool.
- stent 110 after expanding stent 110 to the appropriate diameter, stent 110 may be concentrically placed over stent enclosing mandrel 138 and allowed to radially recoil into position over hourglass shaped mandrel 143 having first graft layer 170 deposited on top.
- stent enclosing mandrel 138 may alternatively be comprised of a cylindrical region instead of a conical region.
- the cylindrical region may have the same diameter as neck region 137 such that the cylindrical region of stent enclosing mandrel 138 may appear as an extension of neck region 137 when stent enclosing mandrel 138 is coupled to stent retaining mandrel 134 .
- stent enclosing mandrel 138 also may be coupled to tapered dilation mandrel 131 ′ which may have second end 133 ′ that is equal in diameter to neck region 137 and smaller in diameter than first end 131 ′.
- Stent enclosing mandrel 138 having the cylindrical region instead of a conical region may be used to encapsulate a stent having a conical region and a neck region that forms a conduit. Any of the methods and techniques described herein to encapsulate the hourglass shaped stent may be used to encapsulate the stent having the cylindrical region instead of the conical region.
- the encapsulated stent may be gently removed from assembly apparatus 130 by sliding the encapsulated stent over the tapered dilation mandrel 132 ′.
- stent enclosing mandrel 138 may be uncoupled from stent retaining mandrel 134 .
- FIGS. 9-11 represent sequential views of the second graft tube 124 being loaded onto the tapered dilation mandrel 131 and being concentrically engaged about the stent member 110 .
- Engagement of second graft tube 124 over tapered dilation mandrel may be facilitated by forming tabs on first end 171 of second graft tube 124 similar to the method described above, involving cutting longitudinal slits (not shown) along diametrically opposed sides of the graft member.
- the tabs can then be used to retain the second graft tube 124 while axial force 170 is applied to assembly apparatus 130 .
- the tabs may be used to manually pull second graft tube 124 over tapered dilation mandrel 131 and hourglass shaped mandrel assembly 143 .
- second graft tube 124 may be engaged with tapered dilatation mandrel 131 in much the same way as first graft tube 122 —by applying axial force 180 to assembly apparatus 130 which causes the tapered dilatation mandrel to pass into and through lumen 173 of second graft tube 124 .
- the inner diameter of second graft tube 124 is radially expanded to that of the outer diameter of second end 133 of tapered dilation mandrel 131 .
- the assembly apparatus 130 is passed into and through lumen 173 of second graft tube 124 until first end 171 of second graft tube 124 is close to large diameter end 142 of stent enclosing mandrel 138 .
- second graft tube 124 undergoes radial recoil so that the inner diameter of second graft tube 124 reduces until it is met with resistance.
- second graft tube 124 is radially recoiled onto stent 110 .
- Second graft tube 124 also may be radially recoiled into cutting crevices 151 and 152 .
- second graft tube 124 may be positioned onto stent 110 via an assembly apparatus 130 that is configured to expand and/or contract radially.
- Assembly apparatus may be comprised of material having expansion properties or contraction properties which may be responsive to exterior conditions.
- hourglass shaped mandrel assembly 143 may be compressible by applying a force normal to the surface of hourglass shaped mandrel 143 .
- assembly apparatus 130 may be comprised of material having a high coefficient of thermal expansion permitting the hourglass shaped assembly to contract when placed in a low temperature environment and expand when placed in a high temperature.
- assembly apparatus may have a rigid core and multiple surfaces that move independently from one another, the surfaces being connected to the core by a number of springs that are configured to permit movement of the surfaces relative to the core when a normal force is applied to the surfaces. For example, a surface may compress towards the core when a normal force is applied and the same surface may expand radially out from the rigid core when the normal force is released.
- the core of the assembly apparatus 130 may have a screw assembly embedded within the core and configured to translate a rotational force applied to the screw assembly into a radial force which is applied to the surfaces to push the surfaces radially outward, or pull the surfaces radially inward.
- Expandable stent 110 having spring tension may be positioned on compressible hourglass shaped mandrel assembly 143 and stent and assembly together may be compressed when a compressive radial force is applied. At a certain compressive force, first end region diameter D 1 and second end region diameter D 2 of stent 110 may be compressed to neck diameter D 3 . In this compressed state, second graft tube 124 may be easily moved axially over compressed stent 110 and first graft layer 170 . Subsequent to positioning second graft tube 124 over compressed stent 110 and first graft layer 170 , compressive force applied to stent 110 and compressible hourglass shaped mandrel assembly 143 may be released. At the same time, hourglass shaped mandrel assembly 143 may expanded. In this way second graft tube 124 may be engaged with stent 110 .
- FIGS. 10 and 11 illustrate the steps for separating second graft tube 124 from stent-graft assembly 120 .
- cutting blades 160 and 161 may again be used to make circumferential cuts in second graft tube 124 at a position near the large diameter ends of stent retaining mandrel 134 and stent encompassing mandrel 138 .
- cutting blades 160 and 161 may make circumferential cuts at the position of cutting crevices 151 and 152 .
- cutting crevices 151 and 152 may be positioned at a length longer than the length of stent 110 to account for recoil of graft material upon being cut.
- second graft layer 190 is deposited onto stent 110 which is positioned over graft layer 170 .
- Second graft layer 190 has a length longer than stent 110 .
- a section of second graft tube 124 extends beyond opposing ends of stent 110 and is similar in length to first graft layer 170 . Waste portion of second graft tube 124 remaining on assembly apparatus 138 may be discarded.
- first graft layer 170 and/or second graft layer 190 may have a length shorter than stent 110 and thus may not extend beyond opposing ends of stent 110 .
- first flared end region 102 or second flared end region 106 may be encapsulated.
- stent 110 takes a different asymmetric shape, such as an hourglass shape on one side and a straight tube shape on the other side, only one portion of asymmetric stent 110 may be encapsulated.
- first graft layer 170 to second graft layer 190 pressure and heat may be applied the stent-graft assembly to achieve sintering.
- Sintering results in strong, smooth, substantially continuous coating that covers the inner and outer surfaces of the stent.
- Sintering may be achieved by first wrapping the ends of first graft layer 170 and second graft layer 190 with strips of tape such as TFE or ePTFE tape to secure the stent-graft assembly to the mandrel.
- tape such as TFE or ePTFE tape
- stent-graft assembly 120 attached to assembly apparatus 130 may be placed in a helical winding wrapping machine which tension wraps the stent-graft assembly 120 with at least one overlapping layer of tape.
- stent-graft assembly 120 may be wrapped with a single overlapping layer of 1 ⁇ 2 inch ePTFE tape with an overlap of the winding of about 70%.
- the force exerted by the TFE or ePTFE wrapping tape compresses the stent-graft assembly against the hourglass shaped mandrel assembly 143 , thereby causing the graft layers to come into intimate contact through interstices of stent 110 .
- interstices exist in the between the struts and sinusoidal rings. Varying tape thickness may reduce or improve ePTFE conformance. For example, thicker tape may result in more compression uniformity than thinner tape material.
- Stent-graft assembly 120 attached to assembly apparatus 130 may then be heated by placing the stent-graft assembly and assembly apparatus into a radiant heat furnace.
- stent-graft assembly 120 may be placed into a radiant heat furnace which had been preheated.
- sintering may be achieved at 327° C.
- the humidity within the radiant heat furnace may preferably be kept low.
- the stent-graft assembly may remain in the radiant heat furnace for a time sufficient for first graft layer 170 to sinter to second graft layer 190 .
- stent-graft assembly 120 may remain in the furnace for about 7-10 minutes.
- the heated assembly may then be allowed to cool for a period of time sufficient to permit manual handling of the assembly.
- the helical wrap may be unwound from stent-graft assembly 120 and discarded.
- the encapsulated stent may then be concentrically rotated about the axis of the mandrel to release any adhesion between the first graft layer 170 and hourglass shaped mandrel assembly 143 .
- the encapsulated stent, still on the mandrel, may then be placed into a laser trimming fixture to trim excess graft materials away from stent-graft assembly 120 .
- the encapsulated stent may be trimmed at various locations along the stent such as in the middle of the stent, thereby creating a partially encapsulated stent.
- first graft layer 170 may be sintered to second graft layer 190 by inducing pressure.
- assembly apparatus 130 or at least hourglass shaped mandrel assembly 143 may have small perforations which may be in fluid communication with a vacuum pump situated in an inner lumen of assembly apparatus 130 or otherwise in fluid communication with an inner lumen of assembly apparatus 130 .
- the assembly apparatus 130 may be placed in a pressurized environment that is pressurized using a compressor pump, for example.
- a balloon such as a Kevlar balloon may also or alternatively be applied to the exterior of the stent-graft assembly to apply pressure to the stent-graft assembly.
- the first graft layer 170 may collapse on the second graft layer 190 forming even adhesion.
- a combination of both pressure and heat may also be used to sinter the first graft layer 170 to the second graft layer 190 . Trimming may then take place in the same manner as described above.
- stent-graft assembly 120 may be removed by decoupling stent retaining mandrel 134 from stent enclosing mandrel 138 .
- stent-graft assembly 120 remains supported by stent retaining mandrel 134 .
- Stent-graft assembly 120 may then be removed from stent retaining mandrel 134 by axially displacing stent-graft assembly 120 relative to stent retaining mandrel 134 .
- stent-graft assembly 120 may be manipulated to a reduced first end region diameter D 1 , second end region diameter D 2 and neck region diameter D 3 .
- the assembly stent-graft assembly may achieve these smaller diametric dimensions by methods such as crimping, calendering, folding, compressing or the like.
- Stent-graft assembly 120 may be constrained at this dimension by disposing stent-graft assembly 120 in a similarly sized cylindrical sheath. Once positioned in the sheath, stent-graft assembly 120 may be delivered to an implantation site using a catheter based system including a delivery catheter.
- the catheter based system may further comprise an engagement component for temporarily affixing stent-graft assembly 120 to the delivery catheter.
- the engagement component may be configured to disengage the stent-graft assembly 120 from the delivery catheter when stent-graft assembly 120 has reached the delivery site.
- the sheath may be removed to release the constraining force and permit the intraluminal stent to elastically expand in the appropriate position.
- stent 110 may be coated with only one layer of biocompatible material.
- stent 110 may be engaged with only first graft layer 170 along an interior surface, following only the appropriate steps set forth above.
- stent 110 may be engaged with only second graft layer 190 along an exterior surface, following only the appropriate steps set forth above.
- stent 110 may be comprised of a plurality of sinusoidal rings connected by longitudinally extending struts. However, it is understood that stent 110 may be constructed from a plurality of interconnected nodes and struts having varying distances and forming various shapes and patterns.
- the inter-nodal-distance (IND) of stent 110 may be manipulated by controlling the tension of the biocompatible material layers during encapsulation.
- the stent may be encapsulated in a manner providing different pulling forces on stent 110 . This may enable different functionality of various areas of the encapsulated stent which are known to be influenced by IND.
- encapsulation may be performed such that stent 110 is constrained in a restricted or contracted state by the encapsulation material.
- the neck diameter may be decreased from 6 mm to 5 mm. This may permit controlled in-vivo expansion to a fully expanded state using, for example, balloon inflation, whereby the constraint is removed. This procedure may be beneficial in a case where a clinical condition dictates an initial restricted state for delivery but requires a larger unconstrained state for implantation or treatment.
- FIGS. 12A-D an alternative method of making stent-graft assembly 120 , as depicted in FIGS. 1-2 , is illustrated.
- FIGS. 12A-D represent sequential views of first graft tube 122 and second graft tube 124 being loaded onto and concentrically engaged about stent graft assembly 120 .
- the process may start by engaging first graft tube 122 over stent 110 .
- Stent 110 may be crimped to a diameter smaller than first graft tube 122 and guided into graft tube 122 .
- first graft tube 122 may be stretched to a diameter slightly larger than stent 110 using an expanding mandrel or other stretching technique and guided over stent 110 .
- second graft tube 124 may be positioned within and along the entire length of stent 110 , shown in FIG. 12B .
- Second graft tube 124 may be pulled through stent 110 while stent 110 remains engaged with first graft tube 122 .
- female mandrel 195 may be introduced near second flared end region 106 of stent 110 .
- Female mandrel 195 may have a similar shape as second flared end region 106 only with slightly smaller dimensions.
- Female mandrel 195 may have receiving portion 196 designed to receive male mandrel 197 .
- female mandrel 195 may be gently advanced within second graft tube 124 until female mandrel 195 takes up nearly the entire space within second flared region 106 .
- second graft tube 124 may be engaged with stent 110 along an interior surface of second flared region 106 and in some embodiments neck region 104 .
- male mandrel 197 may be introduced near first flared end region 102 .
- Male mandrel 197 may be similar in shape to first flared end region 102 only with slightly smaller dimensions.
- Male mandrel 195 may have protruding section 198 sized and shaped to be received by female mandrel 195 . Having a conical shape, male mandrel 197 may be gently advanced within second graft tube 124 toward female mandrel 195 until female assembly 195 takes up nearly the entire space within first flared region 102 and protruding section is fully received by receiving portion 196 . In this manner, second graft tube 124 may be engaged with stent 110 along an interior surface of second flared region 106 and in some embodiments neck region 104 .
- stent 110 may be entirely covered on an exterior surface by first graft tube 122 and entirely covered on an interior surface by second graft tube 124 .
- First graft tube 122 and second graft tube 124 may be appropriately cut away according to the same procedures illustrated in FIGS. 6 and 10 resulting in first graft layer 170 and second graft layer 190 .
- stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bonding first graft layer 170 to second graft layer 190 involving pressure and heat applied to the stent-graft assembly to achieve sintering.
- the mandrel placed in the first flared region 102 may alternatively be a female mandrel and the mandrel placed in second flared region 106 may alternatively be a male mandrel. It is also understood that the process depicted in FIGS. 12A-D may start first with the mandrel entering the first flared region 102 of stent 110 .
- first graft layer 170 may be pre-formed into an hourglass shaped pre-shaped first graft layer 199 using a dedicated mandrel and heat treatment.
- the pre-formed shape may have dimensions similar to that of stent 110 .
- female mandrel 200 may be introduced into one side of pre-shaped first graft layer 199 , such that female mandrel 200 takes up nearly the entire space within one hourglass side of pre-shaped first graft layer 199 as shown in FIG. 13B .
- Female mandrel 200 may have receiving portion 201 designed to receive male mandrel 203 .
- stent 110 may be placed over pre-shaped first graft layer 199 , as show in in FIG. 13C .
- Stent 110 may be positioned over first graft layer 199 or first graft layer 199 may be positioned within stent 110 .
- Stent 110 having a shape similar to that of pre-formed first graft layer 199 should fit into place on pre-formed first graft layer 199 .
- second pre-shaped graft layer 202 formed into an hourglass shape having dimensions similar to stent 110 may be deposited on stent 110 as is illustrated in FIG. 13D .
- Pre-shaped second graft layer 202 may be formed in a similar manner as pre-shaped first graft layer 199 , using a dedicated mandrel and heat treatment.
- Pre-shaped second graft layer 202 may be expanded and positioned over stent 110 .
- Pre-shaped second graft layer 202 may recoil into its pre-shaped form upon releasing any radial expansion force on pre-shaped second graft layer 202 .
- stent 110 may be crimped to facilitate mounting of second graft layer 202 .
- male mandrel 203 may be introduced near the end of pre-formed first graft layer 199 not occupied by female mandrel 200 .
- Male mandrel 203 may be similar in shape to this end of pre-formed first graft layer 199 only with smaller dimensions.
- Male mandrel 203 may be have protruding section 204 sized and shaped to be received by receiving portion 201 of female mandrel 200 . Having a conical shape, male mandrel 203 may be gently advanced within pre-formed first graft layer 199 toward female mandrel 200 until protruding section 204 is fully received by receiving portion 201 .
- stent 110 may be at least partially covered on an exterior surface by pre-shaped second graft layer 202 and at least partially covered on an interior surface by pre-shaped first graft layer 199 .
- Stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bonding first graft layer 170 , in this case pre-shaped first graft layer 199 , to second graft layer 190 , in this case pre-shaped second graft layer 202 . These procedures may involve pressure and heat applied to the stent-graft assembly to achieve sintering. This process simplifies the mounting of the graft tubes and reduces risk of tears and non-uniformities. It is understood that the mandrel inserted first into pre-formed first graft layer 199 may alternatively be a male mandrel and the mandrel inserted second may alternatively be a female mandrel.
- FIGS. 14A-14D another alternative method of making stent-graft assembly 120 , as depicted in FIGS. 1-2 , is illustrated.
- the process may start by engaging first graft tube 122 over stent 110 .
- Stent 110 may be crimped using dedicated crimping tools, such as ones detailed in U.S. Patent Publication No. 2014/0350565 to a diameter smaller than first graft tube 122 and guided into graft tube 122 .
- first graft tube 122 may be stretched to a diameter slightly larger than stent 110 using an expanding mandrel or other stretching mechanism and guided over stent 110 .
- the approach illustrated in FIG. 14A may achieve a firm engagement between crimped stent 110 and the first graft layer 170 , enabling improved encapsulation.
- second graft tube 124 may be positioned within and along the entire length of stent 110 , shown in FIG. 14B .
- Second graft tube 124 may be pulled through stent 110 while stent 110 remains engaged with first graft tube 122 .
- stent 110 with first graft tube 122 engaged with stent 110 may be expanded, using well-known expansion techniques, and positioned over second graft tube 124 .
- balloon catheter 205 having inflatable balloon 206 may be inserted into second graft tube 124 such that the balloon catheter 205 is surrounded by stent 110 and first graft layer 122 .
- second graft tube 124 may be positioned over inflatable balloon 206 and inflatable balloon 206 may be positioned within stent 110 via balloon catheter 205 .
- inflatable balloon 206 of balloon catheter 205 may be inflated to engage second graft tube 124 with an interior surface of stent 110 .
- inflatable balloon 206 to engage second graft layer 124 with stent 110 permits uniform contact between and engagement between second graft tube 124 and stent 110 as well as second graft tube 124 and first graft layer 122 between the interstices of stent 110 , thus optimizing the adhesion during encapsulation.
- the degree of inflation may be manipulated to achieve a desired pressure within the balloon and a desired adhesion between first graft tube 122 and the second graft tube 124 .
- the degree of inflation may be manipulated to achieve a desired inter-nodal-distance of the graft material. Different pressures may also be achieved by varying the wall thickness of the balloon. Furthermore, interlocking balloons may be used to reduce bond lines.
- First graft tube 122 and second graft tube 124 may be appropriately cut away according to the same procedures illustrated in FIGS. 6 and 10 resulting first graft layer 170 and second graft layer 190 .
- stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bonding first graft layer 170 to second graft layer 190 involving pressure and heat applied to the stent-graft assembly to achieve sintering.
- FIGS. 15A-15F another alternative method of making stent-graft assembly 120 , as depicted in FIGS. 1-2 , is illustrated.
- the process may start by placing stent 110 within funnel 207 and advancing stent 207 within funnel 207 towards a reduced section of funnel 207 , using, for example, a dedicated pusher tool like the one described in U.S. Patent Publication No. 2014/0350565, to reduce the diameter of stent 110 .
- Stent 110 may be constructed in a manner that, upon reduction caused by funnel 207 , the shape of stent 110 morphs such that the flared ends are tapered and eventually turned inward toward a longitudinal axis of stent 110 , resulting in stent 110 having a substantially reduced cross-sectional diameter.
- funnel 207 may have introducer tube 208 extending from the narrow side of the funnel 207 which may receive stent 110 after stent 110 has been fully restricted by funnel 207 .
- Introducer tube 208 may have a diameter smaller than that of first graft tube 122 . Introducer tube may thus be inserted into first graft tube 122 , as is illustrated in FIG. 15C , and stent 110 having the reduced diameter, may be advanced out of introducer tube 208 and into first graft tube 122 .
- stent 110 is illustrated after having been advanced from introducer tube 208 and into first graft tube 124 .
- stent 110 may expand radially to a diameter larger than the diameter of first graft tube 122 , thereby engaging first graft tube 122 along the outer surface of stent 110 .
- An end of first graft tube 122 may have been positioned a distance beyond introducer tube 208 such that upon depositing stent 110 into first graft tube 122 , remaining portion 209 of first graft tube 122 extends beyond stent 110 a distance of more than one length of stent 110 .
- first graft tube 122 may be used as a second graft layer along the internal surface of stent 110 by pushing remaining portion 209 through the interior of stent 110 and out an opposing side of stent 110 , in the direction indicated by the arrows in FIG. 15D .
- first graft layer 122 may extend along an exterior surface of stent 110 , curve around an end of stent 110 and travel along the interior of stent 110 .
- female mandrel 200 having receiving portion 201 and male mandrel 203 having protruding section 204 may be inserted into the stent-graft combination.
- Female mandrel 200 may be introduced first to one end of the stent-graft combination having a size slightly larger than the dimensions of female mandrel 200 .
- male mandrel 203 may be introduced into the opposing end of the stent-graft combination and advanced until protruding section 204 is received by receiving section 201 .
- stent 110 may be guided into its original hour-glass shape. This method may induce improved adhesion between first graft tube 122 , remaining portion 209 and stent 110 .
- first graft tube 122 and remaining portion 209 may be appropriately cut away according to the same procedures illustrated in FIGS. 6 and 10 resulting first graft layer 170 and second graft layer 190 , with the exception that only one side of stent graft assembly needs to be cut or otherwise removed first graft tube 122 and remaining portion 209 .
- Stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bonding first graft layer 170 to second graft layer 190 involving pressure and heat applied to the stent-graft assembly to achieve sintering. It is also understood that the process depicted in FIGS. 15F may start with the male mandrel entering the stent graft combination first.
- assembly mandrel 130 may include additional or fewer components of various sizes and composition.
- stent encapsulation is described herein, it is understood that the same procedures may be used to encapsulate any other bio-compatible material. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.
Abstract
Systems and methods for the manufacture of an hourglass shaped stent-graft assembly comprising an hourglass shaped stent, graft layers, and an assembly mandrel having an hourglass shaped mandrel portion. Hourglass shaped stent may have superelastic and self-expanding properties. Hourglass shaped stent may be encapsulated using hourglass shaped mandrel assembly coupled to a dilatation mandrel used for depositing graft layers upon hourglass shaped mandrel assembly. Hourglass shaped mandrel assembly may have removably coupled conical portions. The stent-graft assembly may be compressed and heated to form a monolithic layer of biocompatible material. Encapsulated hourglass shaped stents may be used to treat subjects suffering from heart failure by implanting the encapsulated stent securely in the atrial septum to allow blood flow from the left atrium to the right atrium when blood pressure in the left atrium exceeds that on the right atrium. The encapsulated stents may also be used to treat pulmonary hypertension.
Description
- This application claims priority to U.S. Provisional Patent Application No. 62/343,658, filed May 31, 2016, the entire contents of which are incorporated herein by reference.
- This application relates to systems and methods for the manufacture of hourglass or “diabolo” shaped encapsulated stents for treating congestive heart failure and other disorders treated with encapsulated hourglass shaped stents.
- Heart failure is the physiological state in which cardiac output is insufficient to meet the needs of the body and the lungs. Congestive Heart Failure (CHF) occurs when cardiac output is relatively low due to reduced contractility or heart muscle thickening or stiffness. There are many possible underlying causes of CHF, including myocardial infarction, coronary artery disease, valvular disease, and myocarditis.
- CHF is associated with neurohormonal activation and alterations in autonomic control. Although these compensatory neurohormonal mechanisms provide valuable support for the heart under normal physiological circumstances, they also have a fundamental role in the development and subsequent progression of CHF. For example, one of the body's main compensatory mechanisms for reduced blood flow in CHF is to increase the amount of salt and water retained by the kidneys. Retaining salt and water, instead of excreting it into the urine, increases the volume of blood in the bloodstream and helps to maintain blood pressure. However, the larger volume of blood also stretches the heart muscle, enlarging the heart chambers, particularly the ventricles. At a certain amount of stretching, the hearts contractions become weakened, and the heart failure worsens. Another compensatory mechanism is vasoconstriction of the arterial system. This mechanism, like salt and water retention, raises the blood pressure to help maintain adequate perfusion.
- In low ejection fraction (EF) heart failure, high pressures in the heart result from the body's attempt to maintain the high pressures needed for adequate peripheral perfusion. However, the heart weakens as a result of the high pressures, aggravating the disorder. Pressure in the left atrium may exceed 25 mmHg, at which stage, fluids from the blood flowing through the pulmonary circulatory system flow out of the interstitial spaces and into the alveoli, causing pulmonary edema and lung congestion.
- CHF is generally classified as either Heart Failure with reduced Ejection Fraction (HFrEF) or Heart Failure with preserved Ejection Fraction (HFpEF). In HFrEF, the pumping action of the heart is reduced or weakened. A common clinical measurement is the ejection fraction, which is a function of the blood ejected out of the left ventricle (stroke volume), divided by the maximum volume remaining in the left ventricle at the end of diastole or relaxation phase (End Diastolic Volume). A normal ejection fraction is greater than 50%. HFrEF has a decreased ejection fraction of less than 40%. A patient with HFrEF may usually have a larger left ventricle because of a phenomenon called cardiac remodeling that occurs secondarily to the higher ventricular pressures.
- In HFpEF, the heart generally contracts normally, with a normal ejection fraction, but is stiffer, or less compliant, than a healthy heart would be when relaxing and filling with blood. This stiffness may impede blood from filling the heart, and produce backup into the lungs, which may result in pulmonary venous hypertension and lung edema. HFpEF is more common in patients older than 75 years, especially in women with high blood pressure.
- Both variants of CHF have been treated using pharmacological approaches, which typically involve the use of vasodilators for reducing the workload of the heart by reducing systemic vascular resistance, as well as diuretics, which inhibit fluid accumulation and edema formation, and reduce cardiac filling pressure. However, pharmacological approaches are not always successful, as some people may be resistant or experience significant side effects
- In more severe cases of CHF, assist devices such as mechanical pumps have been used to reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Chronic left ventricular assist devices (LVAD), and cardiac transplantation, often are used as measures of last resort. However, such assist devices are typically intended to improve the pumping capacity of the heart, to increase cardiac output to levels compatible with normal life, and to sustain the patient until a donor heart for transplantation becomes available. Such mechanical devices enable propulsion of significant volumes of blood (liters/min), but are limited by a need for a power supply, relatively large pumps, and the risk of hemolysis, thrombus formation, and infection. In addition to assist devices, surgical approaches such as dynamic cardiomyoplasty or the Batista partial left ventriculectomy may also be used in severe cases. However these approaches are highly invasive and have the general risks associated with highly invasive surgical procedures.
- U.S. Pat. No. 6,468,303 to Amplatz et al. describes a collapsible medical device and associated method for shunting selected organs and vessels. Amplatz describes that the device may be suitable to shunt a septal defect of a patient's heart, for example, by creating a shunt in the atrial septum of a neonate with hypoplastic left heart syndrome (HLHS). Amplatz describes that increasing mixing of pulmonary and systemic venous blood improves oxygen saturation. Amplatz describes that depending on the hemodynamics, the shunting passage can later be closed by an occluding device. However, Amplatz is silent on the treatment of CHF or the reduction of left atrial pressure, and is also silent on means for regulating the rate of blood flow through the device.
- U.S. Pat. No. 8,070,708 to Rottenberg describes a method and device for controlling in-vivo pressure in the body, and in particular, the heart. The device described in Rottenberg involves a shunt to be positioned between two or more lumens in the body to permit fluid to flow between the two lumens. The Rottenberg patent further describes that an adjustable regulation mechanism may be configured to cover an opening of the shunt to regulate flow between the two lumens. The shunt is configured such that the flow permitted is related to a pressure difference between the two lumens. The adjustable regulation mechanism may be remotely activated. The Rottenberg patent describes that the device described may be used to treat CHF by controlling pressure difference between the left atrium and the right atrium. While Rottenberg describes a mechanism for treating CHF by controlling the flow between the left atrium and the right atrium, it does not describe the encapsulation of an hourglass shaped stent.
- U.S. Patent Publication No. 2005/0165344 to Dobak, III describes an apparatus for treating heart failure that includes a conduit positioned in a hole in the atrial septum of the heart, to allow flow from the left atrium into the right atrium. Dobak describes that the shunting of blood will reduce left atrial pressures, thereby preventing pulmonary edema and progressive left ventricular dysfunction, and reducing LVEDP. Dobak describes that the conduit may include a self-expandable tube with retention struts, such as metallic arms that exert a slight force on the atrial septum on both sides and pinch or clamp the valve to the septum, and a one-way valve member, such as a tilting disk, bileaflet design, or a flap valve formed of fixed animal pericardial tissue. However, Dobak states that a valved design may not be optimal due to a risk of blood stasis and thrombus formation on the valve, and that valves can also damage blood components due to turbulent flow effects. Dobak does not provide any specific guidance on how to avoid such problems.
- U.S. Pat. No. 9,034,034 to Nitzan, incorporated herein by reference, describes a device for regulating blood pressure between a patient's left atrium and right atrium which comprises an hourglass-shaped stent having a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum. Nitzan describes that the hourglass shaped stent is also encapsulated with a biocompatible material. While Nitzan describes a method for the manufacture of an hourglass shaped stent for the treatment of CHF, Nitzan is silent on the method of encapsulating the stent.
- U.S. Pat. No. 6,214,039 to Banas, incorporated herein by reference, describes a method for covering a radially endoluminal stent. In the method described by Banas, the encapsulated stent is assembled by joining a dilation mandrel and a stent mandrel, placing the graft on the dilation mandrel where it is radially expanded, and passing the expanded graft over the stent that is positioned on the stent mandrel. While Banas describes a method for encapsulating a cylindrical stent, the method in Banas does not describe encapsulation of an hourglass shaped stent intended for treatment of CHF. The method for assembling the covered stent and mandrel assembly described in Banas would be inappropriate for assembly of an hourglass stent described in Nitzan.
- U.S. Pat. No. 6,797,217 to McCrea, incorporated herein by reference, describes a method for encapsulating stent grafts. McCrea describes methods for encapsulating an endoluminal stent fabricated from a shape memory alloy. The Method described by McCrea involves an endoluminal stent encapsulated in an ePTFE covering which circumferentially covers both the luminal and abluminal walls along at least a portion of the longitudinal extent of the endoluminal stent. McCrea further describes applying pressure to the stent-graft assembly and heating the assembly to complete the encapsulation. While McCrea describes an encapsulated endoluminal stent, it does not describe the encapsulation of an hourglass shaped stent for the treatment of CHF.
- In view of the above-noted drawbacks of previously known systems, it would be desirable to provide systems and methods of manufacture of encapsulated hourglass shaped stents for treating congestive heart failure and other disorders treated with hourglass shaped stent-graft assemblies.
- The present invention overcomes the drawbacks of previously-known systems and methods by providing systems and methods for making encapsulated hourglass shaped stents for treating CHF and other conditions benefited by encapsulated hourglass shaped stents such as pulmonary hypertension. The hourglass or “diabolo” shaped stents are configured to be encapsulated using a mandrel assembly.
- In accordance with one aspect, a method for making an encapsulated stent-graft may involve, providing a mandrel having a first conical region with a first apex and a second conical region with a second apex, placing an expandable stent having an hourglass shape in an expanded form on the mandrel so that a first flared end region of the expandable stent conforms to the first conical region and a second flared end region of the expandable stent conforms to the second conical region, associating a biocompatible material with the expandable stent to form a stent-graft assembly, and compressing the stent-graft assembly against the mandrel to form the encapsulated stent-graft. The first conical region and the second conical region may be aligned so that the first and second apexes contact one another.
- The biocompatible material may have first and second ends and associating the biocompatible material with the expandable stent involves placing the biocompatible material within a lumen of the expandable stent. The method may further include placing a second biocompatible material over the expandable stent. Compressing the stent-graft assembly may involve winding a layer of tape over the biocompatible material to compress the stent-graft assembly against the mandrel. The expandable stent may include through-wall openings, and the method may further involve heating the stent-graft assembly to cause the biocompatible material and the second biocompatible material to bond to one another through the through-wall openings. Heating the stent-graft assembly may cause the biocompatible material and the second biocompatible material to become sintered together to form a monolithic layer of biocompatible material. The method may further involve applying a layer of Fluorinated Ethylene Propylene (FEP) to biocompatible material or second biocompatible material. The biocompatible material may be pre-formed. The method may further involve manipulating the encapsulated stent-graft to a compressed shape and loading the encapsulated stent-graft into a delivery sheath. A first end diameter of the expandable stent may be different in size from a second end diameter. The mandrel may have a neck region disposed between a first conical region and a second conical region and the mandrel may be configured to be removably uncoupled at the neck region into a first half having at least the first conical region and a second half having at least the second conical region.
- In accordance with another aspect, a method for making an encapsulated stent-graft may involve providing a mandrel assembly having an asymmetric shape, providing an expandable stent in an expanded form, coupling a biocompatible material to the expandable stent to form a stent-graft assembly, and compressing the stent-graft assembly on the mandrel assembly to form the encapsulated stent-graft. The expandable stent may be configured to conform to the asymmetric shape formed by the mandrel assembly.
- The expandable stent and the biocompatible material may be coupled on the mandrel assembly or before placement on the mandrel assembly. The method may further involve coupling a second biocompatible material to an opposing surface of the expandable stent to form the stent-graft assembly. The second biocompatible material may be formed of a same or different material as the biocompatible material. The mandrel assembly may include a first mandrel and a second mandrel, and the method may further involve, positioning the first mandrel within the first end of the expandable stent such that a portion of the second biocompatible material is positioned between the first mandrel and the expandable stent, and positioning the second mandrel within the second end of the expandable stent such that a portion of the second biocompatible material is positioned between the second mandrel and the expandable stent. The biocompatible material may be a pre-formed biocompatible graft layer having the expandable stent. The pre-formed biocompatible graft layer may engage the expandable stent on the mandrel assembly.
- In accordance with yet another aspect, a method for making an encapsulated stent-graft may involve providing an asymmetrical stent, placing a first biocompatible material over the asymmetrical stent, providing a second biocompatible material for placement within the asymmetrical stent, inserting a balloon catheter having an inflatable balloon within the asymmetrical stent in a deflated state such that the second biocompatible material is between the asymmetrical stent and the inflatable balloon, and inflating the inflatable balloon to an inflated state conforming to the shape of the asymmetrical stent, thereby causing the second biocompatible material to engage with the asymmetrical stent to form the encapsulated stent-graft.
- The method may further involve controlling the pressure within the balloon to achieve a desired adhesion between the first biocompatible material and the second biocompatible material. The method may further involve controlling the pressure within the balloon to achieve a desired inter-nodal-distance of the graft material. The second biocompatible material may be placed within the asymmetrical stent prior to inserting the balloon catheter within the asymmetrical stent. The second biocompatible material may be disposed on the inflatable balloon, and inflating the inflatable balloon may cause the second biocompatible material disposed on the inflatable balloon to contact and inner surface of the asymmetrical stent thereby engaging the second biocompatible material with the asymmetrical stent.
- In accordance with yet another aspect, a method for making an encapsulated stent-graft may involve providing a funnel having a large end and a small end, placing an asymmetric stent with a first end, a second end, an exterior surface and an interior surface within the large end of the funnel, placing a biocompatible tube over the small end of the funnel, the biocompatible tube having a stent receiving portion and a remaining portion, advancing the asymmetric stent through the funnel and out the small end of the funnel, thereby depositing the asymmetric stent into the biocompatible tube such that the stent is positioned within the stent receiving portion of the biocompatible tube, thereby engaging an exterior surface of the asymmetric stent with the biocompatible tube, pulling the remaining portion of the biocompatible tube through the first end of the asymmetric stent and out the second end, introducing a first mandrel having a shape similar to the first side of the asymmetric stent into the first side of asymmetric stent thereby engaging the interior surface of the first side of the asymmetric stent with a portion of the remaining portion of the biocompatible tube, and introducing a second mandrel having a shape similar to the second side of the asymmetric stent into the second side of the asymmetric stent thereby engaging the interior surface of the second side of the asymmetric stent with a portion of the remaining portion of the biocompatible tube.
- In accordance with yet another aspect, an hourglass shaped mandrel assembly for making an encapsulated stent-graft may involve a first portion having at least a first conical region having a flared end with a first diameter and an apex end with a second diameter, a second portion having at least a second conical region having a flared end with third diameter and an apex end with a fourth diameter, and a tapered region coupled to the flared end of the first portion and extending away from the flared end of the first portion. The tapered region may have a flared end with a fifth diameter and a tapered end with a sixth diameter such that the fifth diameter is equal to the first diameter and the sixth diameter is smaller than the fifth diameter. The first conical region of the first portion and the second conical region of the second portion may be aligned so that apexes of the first portion and second portion are contacting one another. The hourglass shaped mandrel assembly may further include a neck region positioned between the apex end of the first portion and the apex end of the second portion such that the neck region is affixed to at least the first portion or the second portion. The first portion and the second portion may be removably coupled at the apex end of the first portion and the apex end of the second portion. The hourglass shaped mandrel may be configured to expand radially.
-
FIG. 1 is side view of hourglass shaped stent constructed in accordance with the methods of the present invention. -
FIG. 2 is a cross-section view of hourglass shaped stent encapsulated with first and second graft layers. -
FIG. 3 is a partially exploded side view of assembly apparatus for manufacturing hourglass stent-graft assembly in accordance with the methods of the present invention. -
FIG. 4 is a side view of hourglass shaped mandrel assembly section of assembly apparatus for manufacturing hourglass shaped stent-graft assembly in accordance with the methods of the present invention. -
FIG. 5 is a side view of assembly apparatus engaged with first graft tube at the tapered region. -
FIG. 6 is a side view of assembly apparatus engaged with first graft tube over hourglass shaped mandrel assembly section. -
FIG. 7 is a side view of first graft layer disposed over hourglass shaped mandrel assembly section of assembly apparatus. -
FIGS. 8A-8C are side views of assembly apparatus engaged with first graft layer and hourglass shaped stent. -
FIG. 9 is a side view of assembly apparatus engaged with second graft tube at the tapered region. -
FIG. 10 is a side view of assembly apparatus engaged with second graft tube over hourglass shaped mandrel assembly section of assembly apparatus. -
FIG. 11 is a side view of stent-graft disposed over hourglass shaped mandrel assembly section. -
FIGS. 12A-12D are side views sequentially illustrating an encapsulation technique involving a male and female mandrel. -
FIGS. 13A-13E are side views sequentially illustrating an encapsulation technique involving pre-shaped grafts and a male and female mandrel. -
FIGS. 14A-14D are side views sequentially illustrating an encapsulation technique involving an inflatable balloon. -
FIGS. 15A-15F are side views sequentially illustrating an encapsulation technique involving a funnel and a male and female mandrel. - Embodiments of the present invention are directed to systems and methods for the manufacture of hourglass or “diabolo” shaped stents encapsulated with biocompatible material for treating subjects suffering from congestive heart failure (CHF) or alternatively pulmonary hypertension. The hourglass or “diabolo” shaped stents are configured to be encapsulated using an hourglass shaped mandrel assembly having a dilation portion and two conical regions that may be removably coupled. The hourglass shaped stents may be specifically configured to be lodged securely in the atrial septum, preferably the fossa ovalis, to allow blood flow from the left atrium to the right when blood pressure in the left atrium exceeds that on the right atrium. The resulting encapsulated stents are particularly useful for the purpose of inter-atrial shunting as they provide long-term patency and prevent tissue ingrowth within the lumen of the encapsulated stent. However, it is understood that the systems and methods described herein may also be applicable to other conditions benefited from an encapsulated hourglass shaped stent such as pulmonary hypertension wherein the encapsulated hourglass shaped stent is used as a right-to-left shunt.
- Referring now to
FIG. 1 ,stent 110 is illustrated.Stent 110 is hourglass or “diabolo” shaped and may be radially self-expandable. Alternatively,stent 110 may be expandable but not self-expandable. For example,stent 110 may be balloon expandable.Stent 110 has three general regions: first flaredend region 102, second end flaredregion 106, andneck region 104 disposed between the first and second flared end regions. First flaredend region 102 has first end region diameter D1, second flaredend region 106 has second end region diameter D2, andneck region 104 has neck diameter D3. As shown inFIG. 1 ,neck region 104 ofstent 110 is significantly narrower than flaredend regions FIG. 1 ,stent 110 may be asymmetric. For example,stent 110 may be asymmetric to take advantage of the natural features of the atrial septum of the heart as well as the left and right atrium cavities. Alternatively, hourglass shapedstent 110 may be symmetric with the first end region diameter D1 being equal to the second end region diameter D2. First flaredend region 102 and second flaredend region 106 also may have either straight or curved profiles or both. For example, strut 111 has a straight profile and strut 108 has a curved profile. Additionally, first flaredend region 102 and second flaredend region 106 may assume any angular position consistent with the hour-glass configuration. -
Stent 110 is preferably comprised of a self-expanding material having superelastic properties. For example, a shape-memory metal such as nickel titanium (NiTi), also known as NITINOL may be used. Other suitable materials known in the art of deformable stents for percutaneous implantation may alternatively be used such as other shape memory alloys, self-expanding materials, superelastic materials, polymers, and the like. The tube may be laser-cut to define a plurality of struts and connecting members. For example, as illustrated inFIG. 1 , the tube may be laser-cut to define a plurality of sinusoidal rings connected by longitudinally extending struts.Struts FIG. 1 may be laser cut to form an integral piece of unitary construction. Alternatively, struts 111 and sinusoidal rings 112-116 may be separately defined to form different pieces of shape-memory metal and subsequently coupled together to formstent 110. The stent may also be electropolished to reduce thrombogenicity. -
Stent 110 may be expanded on a mandrel to definefirst end region 102,second end region 106, andneck region 104. The expanded stent then may be heated to set the shape ofstent 110. The stent may be expanded on a mandrel in accordance with the teachings of U.S. Pat. No. 9,034,034 to Nitzan, incorporated herein. In one example,stent 110 is formed from a tube of NITINOL, shaped using a shape mandrel, and placed into an oven for 11 minutes at 530° C. to set the shape. The mandrel disclosed inFIGS. 3-4 may be configured as a shaping mandrel to set the shape ofstent 110 or, alternatively, a different mandrel may be used as the shaping mandrel. - Referring now to
FIG. 2 ,stent 110 is at least partially covered with biocompatible material, as shown inFIG. 2 , to create stent-graft assembly 120. Biocompatible material may be expanded polytetrafluoroethylene (ePTFE), silicone, polycarbonate urethane, DACRON (polyethylene terephthalate), Ultra High Molecular Weight Polyethylene (UHMWPE), or polyurethane, or of a natural material such as pericardial tissue, e.g., from an equine, bovine, or porcine source or human tissue such as human placenta or other human tissues. The biocompatible material is preferably smooth so as to inhibit thrombus formation, and optionally may be impregnated with carbon so as to promote tissue ingrowth. Alternatively, to promote tissue ingrowth and endothelization, the biocompatible material may form a mesh-like structure. The biocompatible material may be pre-shaped using a dedicated pre-shaping mandrel and heat treatment to simplify the mounting of the biocompatible material on an encapsulation mandrel, as discussed in detail below. Pre-shaping the biocompatible material has been shown to simplify the handling and mounting of the biocompatible material on the mandrel, thereby reducing stretching and the risk for tears in the biocompatible material and may be especially beneficial for encapsulating asymmetrical stents. Portions ofstent 110 such as first flaredend region 102 may not be covered with the biocompatible material. - Generally, the stent is positioned between a first and second layer of graft material by covering an inner surface of
stent 121 withfirst graft layer 170, and covering the outer surface ofstent 123 withsecond graft layer 190.First graft layer 170 andsecond graft layer 190 each may have a first end and a second end and may have lengths that are about equal. Alternatively,first graft layer 170 andsecond graft layer 190 may have different lengths.Stent 110 may have a length that is shorter than the length offirst graft layer 170 andsecond graft layer 190. In other embodiments,stent 110 may have a length that is longer than the length offirst graft layer 170 and/orsecond graft layer 190. As discussed in detail below, the graft layers may be securely bonded together to form a monolithic layer of biocompatible material. For example, first and second graft tubes may be sintered together to form a strong, smooth, substantially continuous coating that covers the inner and outer surfaces of the stent. Portions of the coating then may be removed as desired from selected portions of the stent using laser-cutting or mechanical cutting, for example. - In a preferred embodiment,
stent 110 is encapsulated with ePTFE. It will be understood by those skilled in the art that ePTFE materials have a characteristic microstructure consisting of nodes and fibrils, with the fibrils orientation being substantially parallel to the axis of longitudinal expansion. Expanded polytetrafluoroethylene materials are made by ram extruding a compressed billet of particulate polytetrafluoroethylene and extrusion lubricant through an extrusion die to form sheet or tubular extrudates. The extrudate is then longitudinally expanded to form the node-fibril microstructure and heated to a temperature at or above the crystalline melt point of polytetrafluoroethylene, i.e., 327° C., for a period of time sufficient to sinter the ePTFE material. Heating may take place in a vacuum chamber to prevent oxidation of the stent. Alternatively, heating may take place in a nitrogen rich environment. A furnace may be used to heat the stent-graft assembly. Alternatively, or in addition to, the mandrel upon which the stent-graft assembly rests may be a heat source used to heat the stent-graft assembly. -
FIGS. 3-11 generally illustrate one method of making stent-graft assembly 120, as depicted inFIGS. 1-2 .FIG. 3 is a partially exploded view ofassembly apparatus 130.Assembly apparatus 130 may comprise tapereddilation mandrel 131,stent retaining mandrel 134 andstent enclosing mandrel 138.Tapered dilation mandrel 131 comprisesfirst end 132 having a taper diameter andsecond end 133 wherein the diameter ofsecond end 133 is greater than the taper diameter. Where other techniques are used to dilatestent 110 and biocompatible graft material, tapereddilation mandrel 131 may not be necessary and thusassembly apparatus 130 may comprisestent retaining mandrel 134 andstent enclosing mandrel 138. -
Stent retaining mandrel 134 may be permanently affixed tosecond end 133 of tapereddilation mandrel 131 or alternatively may be removably coupled to tapered dilation mandrel. For example,stent retaining mandrel 134 may be screwed into tapereddilation mandrel 131 using a screw extending fromstent retaining mandrel 134 and a threaded insert embedded into tapereddilation mandrel 131. However, it will be understood by those in the art that couplings are interchangeable and may be any of a wide variety of suitable couplings. -
Stent retaining mandrel 134 may comprise a conical region defined bylarge diameter end 135 and anapex end 136.Large diameter end 135 may be equal in diameter withsecond end 133 of tapereddilation mandrel 131, and larger in diameter thanapex end 136. It is understood thatstent retaining mandrel 134 may alternatively be other shapes including non-conical shapes.Stent retaining mandrel 134 may optionally incorporateneck region 137.Neck region 137 may extend fromapex end 136, as shown inFIG. 3 , and may have the same diameter asapex end 136. Alternatively,neck region 137 may extend fromstent enclosing mandrel 138. -
Stent enclosing mandrel 138 is removably coupled tostent retaining mandrel 134. For example,stent enclosing mandrel 138 may be screwed intostent retaining mandrel 134 usingscrew 139 extending fromstent enclosing mandrel 138 and threadedinsert 140 embedded intostent retaining mandrel 134. Alternatively, screw 139 may extend fromstent retaining mandrel 134 and threaded insert may be embedded intostent enclosing mandrel 138. While the figures depict threaded coupling, it will be understood by those in the art that the couplings are interchangeable and may be any of a wide variety of suitable couplings. In another example,stent retaining mandrel 134 may be a female mandrel having a receiving portion andstent enclosing mandrel 138 may be a male mandrel having a protruding portion. However, it is understood thatstent retaining mandrel 134 may be a male mandrel having a protruding portion andstent enclosing mandrel 138 may be a female mandrel having a receiving portion. -
Stent enclosing mandrel 138 may comprise a conical region defined bylarge diameter end 142 and anapex end 141, whereinlarge diameter end 142 is larger in diameter thanapex end 141. It is understood thatstent enclosing mandrel 138 alternatively take other shapes including non-conical shapes.Stent enclosing mandrel 138 may be permanently affixed to handlesegment 144 atlarge diameter end 142. Alternatively,stent enclosing mandrel 138 may be removably coupled to handlesegment 144. Wherestent enclosing mandrel 138 is removably coupled to handlesegment 144, handlesegment 144 may be removed and replaced with a taper mandrel segment similar to taperdilation mandrel 131, as shown inFIG. 8C . - Referring to
FIG. 4 , when coupled together,stent retaining mandrel 134 andstent enclosing mandrel 138 form hourglass shapedmandrel assembly 143. Hourglass shapedmandrel assembly 143 is configured such that the conical region ofstent retaining mandrel 134 is oriented toward the conical region ofstent enclosing mandrel 138, whereinapex end 136 ofstent retaining mandrel 138 having extendingneck region 137 is in contact withapex end 141 ofstent enclosing mandrel 138.Neck region 137 is configured to conform to the diameter ofapex end 136 ofstent retaining mandrel 138 andapex end 141 ofstent enclosing mandrel 138, whether or notapex end 141 andapex end 136 are equal in diameter.Neck region 137 may vary in diameter or may be eliminated entirely. - The size and shape of hourglass shaped
mandrel assembly 143 and specifically the size of the conical regions ofstent retaining mandrel 134 andstent enclosing mandrel 138 preferably correspond to the size and shape of flaredend region 102,neck region 104 and second flaredend region 106 ofstent 110. Hourglass shapedmandrel assembly 143 may be asymmetrical such that diameter D4 oflarge diameter end 135 is different than diameter D5 oflarge diameter end 142. Alternatively, diameter D4 and diameter D5 may be the same. Similarly, angle θ1 and angle θ2 may be different, resulting in an asymmetrical mandrel, or may be the same. Angle θ1 and angle θ2 also may vary along the length of hourglass shapedmandrel assembly 143 to better conform tostent 110. While neck diameter D6 may vary at different points alongneck region 137, diameter atneck region 137 is at all times smaller than diameter D4 and D5. -
FIGS. 5-7 , represents sequential views offirst graft tube 122 being loaded onto the tapereddilation mandrel 131 and being concentrically engaged about hourglass shapedassembly 143 in an exemplary sequence. Engagement offirst graft tube 122 over tapereddilation mandrel 131 may be facilitated by forming tabs onfirst end 153 offirst graft tube 122 by cutting longitudinal slits (not shown) along diametrically opposing sides of the graft tube. The tabs can then be used to retainfirst graft tube 122 whileaxial force 150 is applied toassembly apparatus 130. Alternatively, the tabs may be used to manually pullfirst graft tube 122 over tapereddilation mandrel 131 and hourglass shapedmandrel assembly 143. To prevent formation of seams or wrinkles, it is important to avoid applying torsional forces to graft tubes by twisting the graft during engagement of the graft member onto the assembly apparatus. Cuttingcrevice stent retaining mandrel 134 andstent enclosing mandrel 138 to provide a guiding indentation for a cutting element to cutfirst graft tube 122 andsecond graft tube 124. - Referring now to
FIG. 5 ,first graft tube 122 may be engaged with tapereddilatation mandrel 131 by applying anaxial force 150 toassembly apparatus 130 which causes the tapered dilatation mandrel to pass into and throughlumen 154 offirst graft tube 122. Asfirst graft tube 122 passes oversecond end 133 of tapereddilatation mandrel 131, the inner diameter of first graft first 122 is expanded radially to that of the outer diameter ofsecond end 133 of tapereddilation mandrel 131. Asfirst graft tube 122 is moved axially overlarge diameter end 135 ofstent retaining mandrel 134 the inner diameter offirst graft tube 122 is greater than the outside diameter of hourglass shapedmandrel assembly 143.Axial force 150 is applied untilfirst end 153 offirst graft tube 122 is nearlarge diameter end 142 ofstent enclosing mandrel 138. As first graft tube moves axially oversecond end 133 of tapereddilatation mandrel 131 and is positioned over hourglass shapedmandrel assembly 143,first graft tube 122 undergoes radial recoil so that the inner diameter offirst graft tube 122 reduces until it's met with resistance from hourglass shapedmandrel 143. As illustrated inFIG. 6 ,first graft tube 122 has radially recoiled onto hourglass shapedmandrel assembly 143 as well as into cuttingcrevices -
FIGS. 6 and 7 illustrate the steps for separatingfirst graft tube 122 and depositinggraft layer 170 upon hourglass shapedmandrel 143. Cuttingblades first graft tube 122 near the large diameter ends ofstent retaining mandrel 134 andstent enclosing mandrel 138. For example, cutting blades may make circumferential cuts at the position of cuttingcrevices crevices stent 110 to account for recoil of graft material after being cut. Alternatively, where the stent is only partially encapsulated, cuttingcrevices stent 110. After cuttingfirst graft tube 122 with cuttingblades first graft layer 170 is deposited ontostent 110. Alternatively, only cuttingcrevice 151 andcutting blade 160 may be used to create a circumferential cut near the large diameter end ofstent retaining mandrel 134. In this mannerfirst end 153 offirst graft tube 122 having tabs at the end, may serve as one end offirst graft layer 170.First graft layer 170 has a length longer thanstent 110. As such, a section offirst graft layer 170 extends beyond opposing ends ofstent 110. After removing excess grafting material,first graft layer 170 remains on the assembly apparatus and covers hourglass shapedmandrel assembly 143. Tape may be applied tofirst graft layer 170 to securegraft layer 170 tostent retaining mandrel 134. Upon depositingfirst graft layer 170 on hourglass shapedmandrel assembly 143, an optional step involves applying a layer of Fluorinated Ethylene Propylene (FEP), or any other adhesive material, tofirst graft layer 170 for improving adhesion during encapsulation process. - Referring now to
FIGS. 8A-8C , after depositingfirst graft layer 170 on hourglass shapedmandrel assembly 143,stent 110 may be loaded onto hourglass shapedmandrel assembly 143. One method for loadingstent 110 onto hourglass shapedmandrel assembly 143 is to uncouplestent retaining mandrel 134 andstent enclosing mandrel 138. Whenstent retaining mandrel 134 is uncoupled fromstent enclosing mandrel 138, the portion offirst graft layer 170 in contact withstent retaining mandrel 134 andneck region 137 will remain supported by thestent retaining mandrel 134 but the portion that was in contact withstent enclosing mandrel 138 will become unsupported beyondneck region 137. As shown inFIG. 8A , by uncouplingstent retaining mandrel 134 andstent enclosing mandrel 138,stent 110 may be loaded ontostent retaining mandrel 134 over first graft layer. During this step, the unsupported region offirst graft layer 170 may be manipulated in shape and guided through an interior opening ofneck region 104 and through an interior of second flaredend region 106. Wherefirst end 153 offirst graft tube 122 is used as the end offirst graft layer 170, the tabs onfirst end 153 offirst graft tube 122 described above, may be used to help guidefirst graft layer 170 throughstent 110. -
Stent 110 is engaged about thestent retaining mandrel 134 by concentrically positioning thestent 110 overfirst graft layer 170 andstent retaining mandrel 134. When loaded ontostent retaining mandrel 134, first flaredend region 102, andneck region 104 ofstent 110 engage withstent retaining mandrel 134 while second flaredend region 106 does not.Stent retaining mandrel 134 andfirst graft layer 170 are configured to have a combined diameter which is less than the inner diameters of first flaredend region 102 andneck region 104 ofstent 110, allowing stent to slide ontostent retaining mandrel 134. - Referring now to
FIG. 8B , upon loadingstent 110 onstent retaining mandrel 134 andfirst graft layer 170,stent enclosing mandrel 138 is coupled tostent retaining mandrel 134, completing the hourglass shaped mandrel assembly.First graft layer 170 may be manually manipulated to avoid being damaged and prevent the occurrence of any wrinkles during recoupling ofstent enclosing mandrel 138. For example,first graft layer 170 may be held by the tabs described above while the stent enclosing mandrel is recoupled to the stent retaining mandrel. If first graft layer was taped tostent retaining mandrel 134, the tape may be removed after recoupling. Whenstent enclosing mandrel 138 is coupled tostent retaining mandrel 134,stent enclosing mandrel 138 engages bothfirst graft layer 170 and second flaredend region 106 ofstent 110, lockingstent 110 into position betweenlarge diameter end 135 andlarge diameter end 142.Stent enclosing mandrel 138 andfirst graft layer 170 are configured to have a combined outside diameter which is less than the inner diameter of second flaredend region 106 ofstent 110, allowingstent 110 to slide into position onstent enclosing mandrel 138. Upon placingstent 110 on firstgreat layer 170, an optional step involves applying a layer of FEP, or any other adhesive material, tofirst graft layer 170 andstent 110 for improving adhesion during encapsulation process. - While
FIGS. 5-7 illustrate one sequence for generatingfirst graft layer 170, it is appreciated thatfirst graft layer 170 may be deposited ontoassembly apparatus 130 in different ways. For example,first graft layer 170 may not be separated fromfirst graft tube 122 until afterstent 110 has been loaded ontoassembly apparatus 130. In this approach, afterfirst end 153 offirst graft tube 122 is positioned nearlarge diameter end 142 ofstent enclosing mandrel 138 andfirst graft tube 122 undergoes radial recoil so that the inner diameter offirst graft tube 122 reduces until it is met with resistance from hourglass shapedmandrel 143, as shown inFIG. 6 ,stent retaining mandrel 138 may be uncoupled fromstent enclosing mandrel 134. Like in the sequence described above, the portion of the first graft tube extending beyondneck region 137 will become unsupported afterstent enclosing mandrel 138 has been uncoupled. The unsupported region offirst graft tube 122 may then be manipulated in shape and guided through an interior opening ofneck region 104 and through an interior of second flaredend region 106 as described above. After the stent enclosing mandrel has been recoupled as shown inFIGS. 8A-8B and discussed above, cuts may be made usingcutting blades first graft tube 122 fromfirst graft layer 170. - In yet another example,
first graft layer 170 may be deposited onto hourglass shapedmandrel 143 using an electrospinning process. Electrospinning is a process in which polymers are electrospun into ultrafine fibers which are deposited upon a target surface. The electrospinning process involves applying an electric force to draw fibers out of polymer solutions or polymer melts. Using electrospinning, ultrafine fibers, such as ePTFE fibers may be deposited onto hourglass shapedmandrel 143 to formfirst graft layer 170. Assembly apparatus may be continuously rotated about its longitudinal axis to evenly apply the ePTFE fibers. In one example,stent retaining mandrel 134 andstent enclosing mandrel 138 may be coupled together during the electrospinning process. In another example,stent retaining mandrel 134 andstent enclosing mandrel 138 may be uncoupled and the conical region ofstent retaining mandrel 134 includingneck region 137 may be subjected to the electrospinning process separate from the conical region ofstent enclosing mandrel 138. Subsequently, whenstent enclosing mandrel 138 andstent retaining mandrel 134 are coupled together, the ePTFE fibers onstent retaining mandrel 134 may be sintered together to form a continuousfirst graft layer 170.Second graft layer 190 may similarly be deposited using electrospinning. - Referring now to
FIG. 8C ,assembly apparatus 130 may be configured such thatfirst graft tube 122 andsecond graft tube 124 may be loaded ontoassembly apparatus 130 from the side closest tostent enclosing mandrel 138. As discussed above,stent enclosing mandrel 138 may be removably coupled to handlesegment 144. In the alternative configuration shown inFIG. 8C ,stent enclosing mandrel 138 may be uncoupled fromhandle segment 144 and tapereddilation mandrel 131′ may be coupled tostent enclosing mandrel 138 instead. It will be understood by those in the art that the couplings are interchangeable and may be any of a wide variety of suitable couplings.Tapered dilation mandrel 131′ hasfirst end 132′ andsecond end 133′ wherein the diameter ofsecond end 133′ is greater than the diameter offirst end 132′ and the diameter ofsecond end 133′ is equal to the diameter oflarge diameter end 142 ofstent enclosing mandrel 138. In the configuration shown inFIG. 8C ,large diameter end 135 may also perform ashandle segment 144′ for pushing. - Using the configuration shown in
FIG. 8C , anaxial force 165 may be applied toassembly apparatus 130 to cause tapereddilatation mandrel 131′ havingfirst end 132′ to pass into and through the lumen of thefirst graft tube 122. Similarly,axial force 165 may be applied toassembly apparatus 130 to guideassembly apparatus 130, and specificallyfirst end 132′, intostent 110 which is configured to expand as tapereddilatation mandrel 131′ is pushed intostent 110.Axial force 165 may be applied by usinghandle segment 144′ to pushassembly apparatus 130. By engagingfirst end 132′ withexpandable stent 110 exhibiting spring tension,stent 110 may be dilated as it moves along tapereddilatation mandrel 131′. In this manner, first end region diameter D1, second end region diameter D2, and neck diameter D3 ofstent 110, as shown inFIG. 1 , may be expanded to a diameter equal to or larger thanlarge diameter end 142 ofstent enclosing mandrel 138, thus permittingstent 110 to traverselarge diameter end 142. Asstent 110 exhibiting spring tension is passed over hourglass shapedmandrel assembly 143, it encounters no resistance to radial recoil and thus radially recoils into position overfirst graft layer 170 and betweenlarge diameter end 135 andlarge diameter end 142. Alternatively,stent 110 may be expanded to a slightly larger diameter thansecond diameter end 142 by applying a radially expansive force onstent 110 using an external expansion tool. In this example, after expandingstent 110 to the appropriate diameter,stent 110 may be concentrically placed overstent enclosing mandrel 138 and allowed to radially recoil into position over hourglass shapedmandrel 143 havingfirst graft layer 170 deposited on top. - In yet another alternative arrangement,
stent enclosing mandrel 138 may alternatively be comprised of a cylindrical region instead of a conical region. The cylindrical region may have the same diameter asneck region 137 such that the cylindrical region ofstent enclosing mandrel 138 may appear as an extension ofneck region 137 whenstent enclosing mandrel 138 is coupled tostent retaining mandrel 134. In this alternative embodiment,stent enclosing mandrel 138 also may be coupled to tapereddilation mandrel 131′ which may havesecond end 133′ that is equal in diameter toneck region 137 and smaller in diameter thanfirst end 131′.Stent enclosing mandrel 138 having the cylindrical region instead of a conical region, may be used to encapsulate a stent having a conical region and a neck region that forms a conduit. Any of the methods and techniques described herein to encapsulate the hourglass shaped stent may be used to encapsulate the stent having the cylindrical region instead of the conical region. Upon completion of encapsulation, the encapsulated stent may be gently removed fromassembly apparatus 130 by sliding the encapsulated stent over the tapereddilation mandrel 132′. Alternatively,stent enclosing mandrel 138 may be uncoupled fromstent retaining mandrel 134. -
FIGS. 9-11 represent sequential views of thesecond graft tube 124 being loaded onto the tapereddilation mandrel 131 and being concentrically engaged about thestent member 110. Engagement ofsecond graft tube 124 over tapered dilation mandrel may be facilitated by forming tabs onfirst end 171 ofsecond graft tube 124 similar to the method described above, involving cutting longitudinal slits (not shown) along diametrically opposed sides of the graft member. The tabs can then be used to retain thesecond graft tube 124 whileaxial force 170 is applied toassembly apparatus 130. Alternatively, the tabs may be used to manually pullsecond graft tube 124 over tapereddilation mandrel 131 and hourglass shapedmandrel assembly 143. - Referring now to
FIG. 9 ,second graft tube 124 may be engaged with tapereddilatation mandrel 131 in much the same way asfirst graft tube 122—by applying axial force 180 toassembly apparatus 130 which causes the tapered dilatation mandrel to pass into and throughlumen 173 ofsecond graft tube 124. Assecond graft tube 124 passes oversecond end 133 of tapereddilatation mandrel 131, the inner diameter ofsecond graft tube 124 is radially expanded to that of the outer diameter ofsecond end 133 of tapereddilation mandrel 131. Theassembly apparatus 130 is passed into and throughlumen 173 ofsecond graft tube 124 untilfirst end 171 ofsecond graft tube 124 is close tolarge diameter end 142 ofstent enclosing mandrel 138. As second graft tube moves axially overstent 110 and to a position overlarge diameter end 142 ofstent enclosing mandrel 138,second graft tube 124 undergoes radial recoil so that the inner diameter ofsecond graft tube 124 reduces until it is met with resistance. As illustrated in FIG. 10,second graft tube 124 is radially recoiled ontostent 110.Second graft tube 124 also may be radially recoiled into cuttingcrevices - Alternatively,
second graft tube 124 may be positioned ontostent 110 via anassembly apparatus 130 that is configured to expand and/or contract radially. Assembly apparatus may be comprised of material having expansion properties or contraction properties which may be responsive to exterior conditions. For example, hourglass shapedmandrel assembly 143 may be compressible by applying a force normal to the surface of hourglass shapedmandrel 143. Instead,assembly apparatus 130 may be comprised of material having a high coefficient of thermal expansion permitting the hourglass shaped assembly to contract when placed in a low temperature environment and expand when placed in a high temperature. Alternatively, assembly apparatus may have a rigid core and multiple surfaces that move independently from one another, the surfaces being connected to the core by a number of springs that are configured to permit movement of the surfaces relative to the core when a normal force is applied to the surfaces. For example, a surface may compress towards the core when a normal force is applied and the same surface may expand radially out from the rigid core when the normal force is released. In addition, or alternatively, the core of theassembly apparatus 130 may have a screw assembly embedded within the core and configured to translate a rotational force applied to the screw assembly into a radial force which is applied to the surfaces to push the surfaces radially outward, or pull the surfaces radially inward. -
Expandable stent 110 having spring tension may be positioned on compressible hourglass shapedmandrel assembly 143 and stent and assembly together may be compressed when a compressive radial force is applied. At a certain compressive force, first end region diameter D1 and second end region diameter D2 ofstent 110 may be compressed to neck diameter D3. In this compressed state,second graft tube 124 may be easily moved axially overcompressed stent 110 andfirst graft layer 170. Subsequent to positioningsecond graft tube 124 overcompressed stent 110 andfirst graft layer 170, compressive force applied tostent 110 and compressible hourglass shapedmandrel assembly 143 may be released. At the same time, hourglass shapedmandrel assembly 143 may expanded. In this waysecond graft tube 124 may be engaged withstent 110. -
FIGS. 10 and 11 illustrate the steps for separatingsecond graft tube 124 from stent-graft assembly 120. After depositingsecond graft tube 124 onstent 110, cuttingblades second graft tube 124 at a position near the large diameter ends ofstent retaining mandrel 134 andstent encompassing mandrel 138. For example, cuttingblades crevices crevices stent 110 to account for recoil of graft material upon being cut. After cuttingsecond graft tube 124 with cuttingblades second graft layer 190 is deposited ontostent 110 which is positioned overgraft layer 170.Second graft layer 190 has a length longer thanstent 110. As such, a section ofsecond graft tube 124 extends beyond opposing ends ofstent 110 and is similar in length tofirst graft layer 170. Waste portion ofsecond graft tube 124 remaining onassembly apparatus 138 may be discarded. Wherestent 110 is only partially encapsulated,first graft layer 170 and/orsecond graft layer 190 may have a length shorter thanstent 110 and thus may not extend beyond opposing ends ofstent 110. For example, only first flaredend region 102 or second flaredend region 106 may be encapsulated. Wherestent 110 takes a different asymmetric shape, such as an hourglass shape on one side and a straight tube shape on the other side, only one portion ofasymmetric stent 110 may be encapsulated. - To securely bond
first graft layer 170 tosecond graft layer 190, pressure and heat may be applied the stent-graft assembly to achieve sintering. Sintering results in strong, smooth, substantially continuous coating that covers the inner and outer surfaces of the stent. Sintering may be achieved by first wrapping the ends offirst graft layer 170 andsecond graft layer 190 with strips of tape such as TFE or ePTFE tape to secure the stent-graft assembly to the mandrel. To apply pressure, stent-graft assembly 120 attached toassembly apparatus 130 may be placed in a helical winding wrapping machine which tension wraps the stent-graft assembly 120 with at least one overlapping layer of tape. For example, stent-graft assembly 120 may be wrapped with a single overlapping layer of ½ inch ePTFE tape with an overlap of the winding of about 70%. The force exerted by the TFE or ePTFE wrapping tape compresses the stent-graft assembly against the hourglass shapedmandrel assembly 143, thereby causing the graft layers to come into intimate contact through interstices ofstent 110. Instent 110 shown inFIG. 1 , interstices exist in the between the struts and sinusoidal rings. Varying tape thickness may reduce or improve ePTFE conformance. For example, thicker tape may result in more compression uniformity than thinner tape material. - Stent-
graft assembly 120 attached toassembly apparatus 130 may then be heated by placing the stent-graft assembly and assembly apparatus into a radiant heat furnace. For example, stent-graft assembly 120 may be placed into a radiant heat furnace which had been preheated. In one example, sintering may be achieved at 327° C. The humidity within the radiant heat furnace may preferably be kept low. The stent-graft assembly may remain in the radiant heat furnace for a time sufficient forfirst graft layer 170 to sinter tosecond graft layer 190. In one example, stent-graft assembly 120 may remain in the furnace for about 7-10 minutes. The heated assembly may then be allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the helical wrap may be unwound from stent-graft assembly 120 and discarded. The encapsulated stent may then be concentrically rotated about the axis of the mandrel to release any adhesion between thefirst graft layer 170 and hourglass shapedmandrel assembly 143. The encapsulated stent, still on the mandrel, may then be placed into a laser trimming fixture to trim excess graft materials away from stent-graft assembly 120. In addition, the encapsulated stent may be trimmed at various locations along the stent such as in the middle of the stent, thereby creating a partially encapsulated stent. - Alternatively,
first graft layer 170 may be sintered tosecond graft layer 190 by inducing pressure. For example,assembly apparatus 130 or at least hourglass shapedmandrel assembly 143 may have small perforations which may be in fluid communication with a vacuum pump situated in an inner lumen ofassembly apparatus 130 or otherwise in fluid communication with an inner lumen ofassembly apparatus 130. Additionally or alternatively, theassembly apparatus 130 may be placed in a pressurized environment that is pressurized using a compressor pump, for example. In another example, a balloon such as a Kevlar balloon may also or alternatively be applied to the exterior of the stent-graft assembly to apply pressure to the stent-graft assembly. Via the pressure applied, thefirst graft layer 170 may collapse on thesecond graft layer 190 forming even adhesion. A combination of both pressure and heat may also be used to sinter thefirst graft layer 170 to thesecond graft layer 190. Trimming may then take place in the same manner as described above. - After trimming excess graft materials, stent-
graft assembly 120 may be removed by decouplingstent retaining mandrel 134 fromstent enclosing mandrel 138. Upon decouplingstent retaining mandrel 134 andstent enclosing mandrel 138, stent-graft assembly 120 remains supported bystent retaining mandrel 134. Stent-graft assembly 120 may then be removed fromstent retaining mandrel 134 by axially displacing stent-graft assembly 120 relative tostent retaining mandrel 134. - Upon removal of stent-
graft assembly 120 fromassembly apparatus 130, stent-graft assembly 120 may be manipulated to a reduced first end region diameter D1, second end region diameter D2 and neck region diameter D3. The assembly stent-graft assembly may achieve these smaller diametric dimensions by methods such as crimping, calendering, folding, compressing or the like. Stent-graft assembly 120 may be constrained at this dimension by disposing stent-graft assembly 120 in a similarly sized cylindrical sheath. Once positioned in the sheath, stent-graft assembly 120 may be delivered to an implantation site using a catheter based system including a delivery catheter. The catheter based system may further comprise an engagement component for temporarily affixing stent-graft assembly 120 to the delivery catheter. The engagement component may be configured to disengage the stent-graft assembly 120 from the delivery catheter when stent-graft assembly 120 has reached the delivery site. At the delivery site, the sheath may be removed to release the constraining force and permit the intraluminal stent to elastically expand in the appropriate position. - While the approach set forth above describes depositing a layer of biocompatible material on an interior surface of
stent 110 and an exterior surface ofstent 110, it is understood that thestent 110 may be coated with only one layer of biocompatible material. For example,stent 110 may be engaged with onlyfirst graft layer 170 along an interior surface, following only the appropriate steps set forth above. Alternatively,stent 110 may be engaged with onlysecond graft layer 190 along an exterior surface, following only the appropriate steps set forth above. - As explained above,
stent 110 may be comprised of a plurality of sinusoidal rings connected by longitudinally extending struts. However, it is understood thatstent 110 may be constructed from a plurality of interconnected nodes and struts having varying distances and forming various shapes and patterns. In one embodiment the inter-nodal-distance (IND) ofstent 110 may be manipulated by controlling the tension of the biocompatible material layers during encapsulation. For example, the stent may be encapsulated in a manner providing different pulling forces onstent 110. This may enable different functionality of various areas of the encapsulated stent which are known to be influenced by IND. In one example, by controlling tension of the biocompatible material layers during encapsulation, different functionality of various areas with respect to tissue ingrowth characteristics may be achieved. Further, it is understood that encapsulation may be performed such thatstent 110 is constrained in a restricted or contracted state by the encapsulation material. For example, the neck diameter may be decreased from 6 mm to 5 mm. This may permit controlled in-vivo expansion to a fully expanded state using, for example, balloon inflation, whereby the constraint is removed. This procedure may be beneficial in a case where a clinical condition dictates an initial restricted state for delivery but requires a larger unconstrained state for implantation or treatment. - Referring now to
FIGS. 12A-D , an alternative method of making stent-graft assembly 120, as depicted inFIGS. 1-2 , is illustrated.FIGS. 12A-D represent sequential views offirst graft tube 122 andsecond graft tube 124 being loaded onto and concentrically engaged aboutstent graft assembly 120. As shown inFIG. 12A the process may start by engagingfirst graft tube 122 overstent 110.Stent 110 may be crimped to a diameter smaller thanfirst graft tube 122 and guided intograft tube 122. Alternatively, or in addition to,first graft tube 122 may be stretched to a diameter slightly larger thanstent 110 using an expanding mandrel or other stretching technique and guided overstent 110. - Upon positioning
first graft tube 122 overstent 110,second graft tube 124 may be positioned within and along the entire length ofstent 110, shown inFIG. 12B .Second graft tube 124 may be pulled throughstent 110 whilestent 110 remains engaged withfirst graft tube 122. Subsequently, as shown inFIG. 12C ,female mandrel 195 may be introduced near second flaredend region 106 ofstent 110.Female mandrel 195 may have a similar shape as second flaredend region 106 only with slightly smaller dimensions.Female mandrel 195 may have receiving portion 196 designed to receivemale mandrel 197. Having a conical shape,female mandrel 195 may be gently advanced withinsecond graft tube 124 untilfemale mandrel 195 takes up nearly the entire space within second flaredregion 106. In this manner,second graft tube 124 may be engaged withstent 110 along an interior surface of second flaredregion 106 and in someembodiments neck region 104. - Referring now to
FIG. 12D ,male mandrel 197 may be introduced near first flaredend region 102.Male mandrel 197 may be similar in shape to first flaredend region 102 only with slightly smaller dimensions.Male mandrel 195 may have protrudingsection 198 sized and shaped to be received byfemale mandrel 195. Having a conical shape,male mandrel 197 may be gently advanced withinsecond graft tube 124 towardfemale mandrel 195 untilfemale assembly 195 takes up nearly the entire space within first flaredregion 102 and protruding section is fully received by receiving portion 196. In this manner,second graft tube 124 may be engaged withstent 110 along an interior surface of second flaredregion 106 and in someembodiments neck region 104. - Upon engaging
female mandrel 195 andmale mandrel 197,stent 110 may be entirely covered on an exterior surface byfirst graft tube 122 and entirely covered on an interior surface bysecond graft tube 124.First graft tube 122 andsecond graft tube 124 may be appropriately cut away according to the same procedures illustrated inFIGS. 6 and 10 resulting infirst graft layer 170 andsecond graft layer 190. Further,stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bondingfirst graft layer 170 tosecond graft layer 190 involving pressure and heat applied to the stent-graft assembly to achieve sintering. It is understood that the mandrel placed in the first flaredregion 102 may alternatively be a female mandrel and the mandrel placed in second flaredregion 106 may alternatively be a male mandrel. It is also understood that the process depicted inFIGS. 12A-D may start first with the mandrel entering the first flaredregion 102 ofstent 110. - Referring now to
FIGS. 13A-13E , another alternative method of making stent-graft assembly 120, as depicted inFIGS. 1-2 , is illustrated. As shown inFIG. 13A ,first graft layer 170 may be pre-formed into an hourglass shaped pre-shapedfirst graft layer 199 using a dedicated mandrel and heat treatment. The pre-formed shape may have dimensions similar to that ofstent 110. Upon forming pre-shapedfirst graft layer 199,female mandrel 200 may be introduced into one side of pre-shapedfirst graft layer 199, such thatfemale mandrel 200 takes up nearly the entire space within one hourglass side of pre-shapedfirst graft layer 199 as shown inFIG. 13B .Female mandrel 200 may have receivingportion 201 designed to receivemale mandrel 203. - Upon placing
female mandrel 200 within pre-formedfirst graft layer 199,stent 110 may be placed over pre-shapedfirst graft layer 199, as show in inFIG. 13C .Stent 110 may be positioned overfirst graft layer 199 orfirst graft layer 199 may be positioned withinstent 110.Stent 110, having a shape similar to that of pre-formedfirst graft layer 199 should fit into place on pre-formedfirst graft layer 199. - Once
stent 110 is deposited on pre-shapedfirst graft layer 199, secondpre-shaped graft layer 202, formed into an hourglass shape having dimensions similar tostent 110 may be deposited onstent 110 as is illustrated inFIG. 13D . Pre-shapedsecond graft layer 202 may be formed in a similar manner as pre-shapedfirst graft layer 199, using a dedicated mandrel and heat treatment. Pre-shapedsecond graft layer 202 may be expanded and positioned overstent 110. Pre-shapedsecond graft layer 202, may recoil into its pre-shaped form upon releasing any radial expansion force on pre-shapedsecond graft layer 202. Alternatively, or in addition to,stent 110 may be crimped to facilitate mounting ofsecond graft layer 202. - Referring now to
FIG. 13E ,male mandrel 203 may be introduced near the end of pre-formedfirst graft layer 199 not occupied byfemale mandrel 200.Male mandrel 203 may be similar in shape to this end of pre-formedfirst graft layer 199 only with smaller dimensions.Male mandrel 203 may be have protrudingsection 204 sized and shaped to be received by receivingportion 201 offemale mandrel 200. Having a conical shape,male mandrel 203 may be gently advanced within pre-formedfirst graft layer 199 towardfemale mandrel 200 until protrudingsection 204 is fully received by receivingportion 201. - Upon engaging
female mandrel 200 andmale mandrel 203,stent 110 may be at least partially covered on an exterior surface by pre-shapedsecond graft layer 202 and at least partially covered on an interior surface by pre-shapedfirst graft layer 199.Stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bondingfirst graft layer 170, in this case pre-shapedfirst graft layer 199, tosecond graft layer 190, in this case pre-shapedsecond graft layer 202. These procedures may involve pressure and heat applied to the stent-graft assembly to achieve sintering. This process simplifies the mounting of the graft tubes and reduces risk of tears and non-uniformities. It is understood that the mandrel inserted first into pre-formedfirst graft layer 199 may alternatively be a male mandrel and the mandrel inserted second may alternatively be a female mandrel. - Referring now to
FIGS. 14A-14D , another alternative method of making stent-graft assembly 120, as depicted inFIGS. 1-2 , is illustrated. As shown inFIG. 14A , the process may start by engagingfirst graft tube 122 overstent 110.Stent 110 may be crimped using dedicated crimping tools, such as ones detailed in U.S. Patent Publication No. 2014/0350565 to a diameter smaller thanfirst graft tube 122 and guided intograft tube 122. Alternatively, or in addition to,first graft tube 122 may be stretched to a diameter slightly larger thanstent 110 using an expanding mandrel or other stretching mechanism and guided overstent 110. The approach illustrated inFIG. 14A may achieve a firm engagement betweencrimped stent 110 and thefirst graft layer 170, enabling improved encapsulation. - Upon positioning
first graft tube 122 overstent 110,second graft tube 124 may be positioned within and along the entire length ofstent 110, shown inFIG. 14B .Second graft tube 124 may be pulled throughstent 110 whilestent 110 remains engaged withfirst graft tube 122. Alternatively,stent 110, withfirst graft tube 122 engaged withstent 110 may be expanded, using well-known expansion techniques, and positioned oversecond graft tube 124. Subsequently, as shown inFIG. 14C ,balloon catheter 205 havinginflatable balloon 206 may be inserted intosecond graft tube 124 such that theballoon catheter 205 is surrounded bystent 110 andfirst graft layer 122. Alternatively,second graft tube 124 may be positioned overinflatable balloon 206 andinflatable balloon 206 may be positioned withinstent 110 viaballoon catheter 205. - Referring now to
FIG. 14D , upon positioningballoon catheter 205 intosecond graft tube 124,inflatable balloon 206 ofballoon catheter 205 may be inflated to engagesecond graft tube 124 with an interior surface ofstent 110. Usinginflatable balloon 206 to engagesecond graft layer 124 withstent 110 permits uniform contact between and engagement betweensecond graft tube 124 andstent 110 as well assecond graft tube 124 andfirst graft layer 122 between the interstices ofstent 110, thus optimizing the adhesion during encapsulation. The degree of inflation may be manipulated to achieve a desired pressure within the balloon and a desired adhesion betweenfirst graft tube 122 and thesecond graft tube 124. Additionally, the degree of inflation may be manipulated to achieve a desired inter-nodal-distance of the graft material. Different pressures may also be achieved by varying the wall thickness of the balloon. Furthermore, interlocking balloons may be used to reduce bond lines. -
First graft tube 122 andsecond graft tube 124 may be appropriately cut away according to the same procedures illustrated inFIGS. 6 and 10 resultingfirst graft layer 170 andsecond graft layer 190. Further,stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bondingfirst graft layer 170 tosecond graft layer 190 involving pressure and heat applied to the stent-graft assembly to achieve sintering. - Referring now to
FIGS. 15A-15F , another alternative method of making stent-graft assembly 120, as depicted inFIGS. 1-2 , is illustrated. As shown inFIG. 15A , the process may start by placingstent 110 withinfunnel 207 and advancingstent 207 withinfunnel 207 towards a reduced section offunnel 207, using, for example, a dedicated pusher tool like the one described in U.S. Patent Publication No. 2014/0350565, to reduce the diameter ofstent 110.Stent 110 may be constructed in a manner that, upon reduction caused byfunnel 207, the shape ofstent 110 morphs such that the flared ends are tapered and eventually turned inward toward a longitudinal axis ofstent 110, resulting instent 110 having a substantially reduced cross-sectional diameter. - As is shown in
FIG. 15B , funnel 207 may haveintroducer tube 208 extending from the narrow side of thefunnel 207 which may receivestent 110 afterstent 110 has been fully restricted byfunnel 207.Introducer tube 208 may have a diameter smaller than that offirst graft tube 122. Introducer tube may thus be inserted intofirst graft tube 122, as is illustrated inFIG. 15C , andstent 110 having the reduced diameter, may be advanced out ofintroducer tube 208 and intofirst graft tube 122. - Referring now to
FIG. 15D ,stent 110 is illustrated after having been advanced fromintroducer tube 208 and intofirst graft tube 124. As is shown inFIG. 15D , upon the removal of inward radial force fromintroducer tube 208,stent 110 may expand radially to a diameter larger than the diameter offirst graft tube 122, thereby engagingfirst graft tube 122 along the outer surface ofstent 110. An end offirst graft tube 122 may have been positioned a distance beyondintroducer tube 208 such that upon depositingstent 110 intofirst graft tube 122, remainingportion 209 offirst graft tube 122 extends beyond stent 110 a distance of more than one length ofstent 110. - Referring now to
FIG. 15E , remaining portion offirst graft tube 122 may be used as a second graft layer along the internal surface ofstent 110 by pushing remainingportion 209 through the interior ofstent 110 and out an opposing side ofstent 110, in the direction indicated by the arrows inFIG. 15D . In this manner,first graft layer 122 may extend along an exterior surface ofstent 110, curve around an end ofstent 110 and travel along the interior ofstent 110. - To engage remaining
portion 209 with the interior surface ofstent 110,female mandrel 200 having receivingportion 201 andmale mandrel 203 having protrudingsection 204 may be inserted into the stent-graft combination.Female mandrel 200 may be introduced first to one end of the stent-graft combination having a size slightly larger than the dimensions offemale mandrel 200. Subsequently,male mandrel 203 may be introduced into the opposing end of the stent-graft combination and advanced until protrudingsection 204 is received by receivingsection 201. Asfemale mandrel 200 andmale mandrel 201 are inserted,stent 110 may be guided into its original hour-glass shape. This method may induce improved adhesion betweenfirst graft tube 122, remainingportion 209 andstent 110. - Upon engaging
female mandrel 200 andmale mandrel 203,first graft tube 122 and remainingportion 209 may be appropriately cut away according to the same procedures illustrated inFIGS. 6 and 10 resultingfirst graft layer 170 andsecond graft layer 190, with the exception that only one side of stent graft assembly needs to be cut or otherwise removedfirst graft tube 122 and remainingportion 209.Stent graft assembly 120 may be produced using the same procedures detailed above including the procedures for securely bondingfirst graft layer 170 tosecond graft layer 190 involving pressure and heat applied to the stent-graft assembly to achieve sintering. It is also understood that the process depicted inFIGS. 15F may start with the male mandrel entering the stent graft combination first. - While various illustrative embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made therein without departing from the invention. For example,
assembly mandrel 130 may include additional or fewer components of various sizes and composition. Furthermore, while stent encapsulation is described herein, it is understood that the same procedures may be used to encapsulate any other bio-compatible material. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.
Claims (27)
1. A method for making an encapsulated stent-graft, the method comprising:
providing a mandrel comprising a first conical region having a first apex and a second conical region having a second apex, the first conical region and the second conical region aligned so that the first and second apexes contact one another;
placing an expandable stent having an hourglass shape in an expanded form on the mandrel so that a first flared end region of the expandable stent conforms to the first conical region and a second flared end region of the expandable stent conforms to the second conical region;
associating a biocompatible material with the expandable stent to form a stent-graft assembly; and
compressing the stent-graft assembly against the mandrel to form the encapsulated stent-graft.
2. The method of claim 1 , wherein the biocompatible material has first and second ends and associating the biocompatible material with the expandable stent comprises placing the biocompatible material within a lumen of the expandable stent.
3. The method of claim 1 , wherein the biocompatible material has first and second ends and associating the biocompatible material with the expandable stent comprises placing the biocompatible material over the mandrel and within a lumen of the expandable stent.
4. The method of claim 2 , further comprising placing a second biocompatible material over the expandable stent.
5. The method of claim 3 , wherein compressing the stent-graft assembly comprises winding a layer of tape over the biocompatible material to compress the stent-graft assembly against the mandrel.
6. The method of claim 4 , wherein the expandable stent comprises through-wall openings, the method further comprising heating the stent-graft assembly to cause the biocompatible material and the second biocompatible material to bond to one another through the through-wall openings.
7. The method of claim 6 , wherein heating the stent-graft assembly causes the biocompatible material and the second biocompatible material to become sintered together to form a monolithic layer of biocompatible material.
8. The method of claim 1 , further comprising applying a layer of Fluorinated Ethylene Propylene (FEP) to biocompatible material or second biocompatible material.
9. The method of claim 1 , wherein the biocompatible material is pre-formed.
10. The method of claim 1 , further comprising manipulating the encapsulated stent-graft to a compressed shape and loading the encapsulated stent-graft into a delivery sheath.
11. The method of claim 1 , wherein a first end diameter of the expandable stent is different in size from a second end diameter.
12. The method of claim 1 , wherein the mandrel has a neck region disposed between a first conical region and a second conical region, the mandrel configured to be removably uncoupled at the neck region into a first half comprising at least the first conical region and a second half comprising at least the second conical region.
13. An hourglass shaped mandrel assembly comprising:
a first portion comprising at least a first conical region having a flared end with a first diameter and an apex end with a second diameter;
a second portion comprising at least a second conical region having a flared end with third diameter and an apex end with a fourth diameter; and
a tapered region coupled to the flared end of the first portion and extending away from the flared end of the first portion, the tapered region having a flared end with a fifth diameter and a tapered end with a sixth diameter, the fifth diameter being equal to the first diameter and the sixth diameter being smaller than the fifth diameter,
wherein the first conical region of the first portion and the second conical region of the second portion are aligned so that apexes of the first portion and second portion are contacting one another.
14. The hourglass shaped mandrel assembly of claim 13 , further comprising a neck region positioned between the apex end of the first portion and the apex end of the second portion, wherein the neck region is affixed to at least the first portion or the second portion.
15. The hourglass shaped mandrel assembly of claim 13 , wherein the first portion and the second portion are removably coupled at the apex end of the first portion and the apex end of the second portion.
16. The hourglass shaped mandrel assembly of claim 13 , wherein the hourglass shaped mandrel is configured to expand radially.
17. A method for making an encapsulated stent-graft, comprising:
providing a mandrel assembly having an asymmetric shape;
providing an expandable stent in an expanded form, the expandable stent configured to conform to the asymmetric shape formed by the mandrel assembly;
coupling a biocompatible material to the expandable stent to form a stent-graft assembly; and
compressing the stent-graft assembly on the mandrel assembly to form the encapsulated stent-graft.
18. The method of claim 17 , wherein the expandable stent and the biocompatible material are coupled on the mandrel assembly or before placement on the mandrel assembly.
19. The method of claim 17 , further comprising coupling a second biocompatible material to an opposing surface of the expandable stent to form the stent-graft assembly, wherein the second biocompatible material is formed of a same or different material as the biocompatible material.
20. The method of claim 19 , wherein the mandrel assembly comprises a first mandrel and a second mandrel, the method further comprising:
positioning the first mandrel within the first end of the expandable stent such that a portion of the second biocompatible material is positioned between the first mandrel and the expandable stent; and
positioning the second mandrel within the second end of the expandable stent such that a portion of the second biocompatible material is positioned between the second mandrel and the expandable stent.
21. The method of claim 17 , wherein the biocompatible material comprises a pre-formed biocompatible graft layer having the expandable stent;
wherein the pre-formed biocompatible graft layer engages the expandable stent on the mandrel assembly.
22. A method for making an encapsulated stent-graft, comprising:
providing an asymmetrical stent;
placing a first biocompatible material over the asymmetrical stent;
providing a second biocompatible material for placement within the asymmetrical stent;
inserting a balloon catheter having an inflatable balloon within the asymmetrical stent in a deflated state such that the second biocompatible material is between the asymmetrical stent and the inflatable balloon; and
inflating the inflatable balloon to an inflated state conforming to the shape of the asymmetrical stent, thereby causing the second biocompatible material to engage with the asymmetrical stent to form the encapsulated stent-graft.
23. The method of claim 22 , further comprising controlling the pressure within the balloon to achieve a desired adhesion between the first biocompatible material and the second biocompatible material.
24. The method of claim 22 , further comprising controlling the pressure within the balloon to achieve a desired inter-nodal-distance of the graft material.
25. The method of claim 22 , wherein the second biocompatible material is placed within the asymmetrical stent prior to inserting the balloon catheter within the asymmetrical stent.
26. The method of claim 22 , wherein the second biocompatible material is disposed on the inflatable balloon, and wherein inflating the inflatable balloon causes the second biocompatible material disposed on the inflatable balloon to contact and inner surface of the asymmetrical stent thereby engaging the second biocompatible material with the asymmetrical stent.
27. A method for making an encapsulated stent-graft, comprising:
providing a funnel having a large end and a small end;
placing an asymmetric stent with a first end, a second end, an exterior surface and an interior surface within the large end of the funnel;
placing a biocompatible tube over the small end of the funnel, the biocompatible tube having a stent receiving portion and a remaining portion;
advancing the asymmetric stent through the funnel and out the small end of the funnel, thereby depositing the asymmetric stent into the biocompatible tube such that the stent is positioned within the stent receiving portion of the biocompatible tube, thereby engaging an exterior surface of the asymmetric stent with the biocompatible tube;
pulling the remaining portion of the biocompatible tube through the first end of the asymmetric stent and out the second end;
introducing a first mandrel having a shape similar to the first side of the asymmetric stent into the first side of asymmetric stent thereby engaging the interior surface of the first side of the asymmetric stent with a portion of the remaining portion of the biocompatible tube; and
introducing a second mandrel having a shape similar to the second side of the asymmetric stent into the second side of the asymmetric stent thereby engaging the interior surface of the second side of the asymmetric stent with a portion of the remaining portion of the biocompatible tube.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/608,948 US20170340460A1 (en) | 2016-05-31 | 2017-05-30 | Systems and methods for making encapsulated hourglass shaped stents |
US15/798,250 US11109988B2 (en) | 2016-05-31 | 2017-10-30 | Systems and methods for making encapsulated hourglass shaped stents |
US16/205,213 US10835394B2 (en) | 2016-05-31 | 2018-11-29 | Systems and methods for making encapsulated hourglass shaped stents |
US17/095,615 US11304831B2 (en) | 2016-05-31 | 2020-11-11 | Systems and methods for making encapsulated hourglass shaped stents |
US17/465,791 US11497631B2 (en) | 2016-05-31 | 2021-09-02 | Systems and methods for making encapsulated hourglass shaped stents |
US17/659,312 US11607327B2 (en) | 2016-05-31 | 2022-04-14 | Systems and methods for making encapsulated hourglass shaped stents |
US18/180,068 US20230277343A1 (en) | 2016-05-31 | 2023-03-07 | Systems and methods for making encapsulated hourglass shaped stents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662343658P | 2016-05-31 | 2016-05-31 | |
US15/608,948 US20170340460A1 (en) | 2016-05-31 | 2017-05-30 | Systems and methods for making encapsulated hourglass shaped stents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/060257 Continuation WO2020110048A1 (en) | 2016-05-31 | 2019-11-27 | Systems and methods for making encapsulated hourglass shaped stents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/798,250 Continuation US11109988B2 (en) | 2016-05-31 | 2017-10-30 | Systems and methods for making encapsulated hourglass shaped stents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170340460A1 true US20170340460A1 (en) | 2017-11-30 |
Family
ID=59071030
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/608,948 Abandoned US20170340460A1 (en) | 2016-05-31 | 2017-05-30 | Systems and methods for making encapsulated hourglass shaped stents |
US15/798,250 Active 2038-04-30 US11109988B2 (en) | 2016-05-31 | 2017-10-30 | Systems and methods for making encapsulated hourglass shaped stents |
US17/465,791 Active US11497631B2 (en) | 2016-05-31 | 2021-09-02 | Systems and methods for making encapsulated hourglass shaped stents |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/798,250 Active 2038-04-30 US11109988B2 (en) | 2016-05-31 | 2017-10-30 | Systems and methods for making encapsulated hourglass shaped stents |
US17/465,791 Active US11497631B2 (en) | 2016-05-31 | 2021-09-02 | Systems and methods for making encapsulated hourglass shaped stents |
Country Status (1)
Country | Link |
---|---|
US (3) | US20170340460A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170172771A1 (en) * | 2014-07-20 | 2017-06-22 | Elchanan Bruckheimer | Pulmonary artery implant apparatus and methods of use thereof |
WO2020023505A1 (en) * | 2018-07-23 | 2020-01-30 | Medtronic, Inc. | Electrospun medical devices and methods of making electrospun medical devices |
WO2020156711A1 (en) * | 2019-01-29 | 2020-08-06 | Xeltis Ag | Electrospun cover layer for medical implants |
WO2020260661A1 (en) * | 2019-06-27 | 2020-12-30 | Xeltis Ag | Electrospun heart valves |
US10940296B2 (en) | 2015-05-07 | 2021-03-09 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Temporary interatrial shunts |
CN113329717A (en) * | 2018-11-29 | 2021-08-31 | V-波有限责任公司 | System and method for making a packaged hourglass-shaped stent |
US11160961B2 (en) | 2019-09-09 | 2021-11-02 | Shifamed Holdings, Llc | Adjustable shunts and associated systems and methods |
WO2021231182A1 (en) * | 2020-05-10 | 2021-11-18 | Vitae LLC | Balloon-expandable heart valve system and method of implantation |
US11234702B1 (en) | 2020-11-13 | 2022-02-01 | V-Wave Ltd. | Interatrial shunt having physiologic sensor |
US11253685B2 (en) | 2019-12-05 | 2022-02-22 | Shifamed Holdings, Llc | Implantable shunt systems and methods |
US11253353B2 (en) | 2006-01-23 | 2022-02-22 | V-Wave Ltd. | Heart anchor device |
US11304831B2 (en) | 2016-05-31 | 2022-04-19 | V-Wave Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US11364132B2 (en) | 2017-06-05 | 2022-06-21 | Restore Medical Ltd. | Double walled fixed length stent like apparatus and methods of use thereof |
US11382747B2 (en) | 2004-02-03 | 2022-07-12 | V-Wave, Ltd. | Device and method for controlling in-vivo pressure |
US20220241565A1 (en) * | 2018-01-20 | 2022-08-04 | V-Wave Ltd | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same |
US11497631B2 (en) | 2016-05-31 | 2022-11-15 | V-Wave Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US20220371259A1 (en) * | 2021-05-18 | 2022-11-24 | Bcm Co., Ltd. | Method of manufacturing covered stent and covered stent manufactured thereby |
US11622695B1 (en) | 2020-04-23 | 2023-04-11 | Shifamed Holdings, Llc | Intracardiac sensors with switchable configurations and associated systems and methods |
US11633194B2 (en) | 2020-11-12 | 2023-04-25 | Shifamed Holdings, Llc | Adjustable implantable devices and associated methods |
US11723765B2 (en) * | 2010-03-26 | 2023-08-15 | Thubrikar Aortic Valve, Inc. | Valve component, frame component and prosthetic valve device including the same for implantation in a body lumen |
US11744589B2 (en) | 2018-01-20 | 2023-09-05 | V-Wave Ltd. | Devices and methods for providing passage between heart chambers |
US11771434B2 (en) | 2016-09-28 | 2023-10-03 | Restore Medical Ltd. | Artery medical apparatus and methods of use thereof |
US11801369B2 (en) | 2020-08-25 | 2023-10-31 | Shifamed Holdings, Llc | Adjustable interatrial shunts and associated systems and methods |
US11813386B2 (en) | 2022-04-14 | 2023-11-14 | V-Wave Ltd. | Interatrial shunt with expanded neck region |
US11850138B2 (en) | 2009-05-04 | 2023-12-26 | V-Wave Ltd. | Shunt for redistributing atrial blood volume |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2999412B1 (en) | 2013-05-21 | 2020-05-06 | V-Wave Ltd. | Apparatus for delivering devices for reducing left atrial pressure |
US11865282B2 (en) | 2019-05-20 | 2024-01-09 | V-Wave Ltd. | Systems and methods for creating an interatrial shunt |
Family Cites Families (392)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3874388A (en) | 1973-02-12 | 1975-04-01 | Ochsner Med Found Alton | Shunt defect closure system |
US3852334A (en) | 1973-12-17 | 1974-12-03 | American Cyanamid Co | Substituted carbazic acid esters |
US3952334A (en) | 1974-11-29 | 1976-04-27 | General Atomic Company | Biocompatible carbon prosthetic devices |
FR2550583B1 (en) | 1983-08-08 | 1986-03-28 | Delecroix Michel | DEVICE FOR REGULATING A PUMP |
US4665906A (en) | 1983-10-14 | 1987-05-19 | Raychem Corporation | Medical devices incorporating sim alloy elements |
US5190546A (en) | 1983-10-14 | 1993-03-02 | Raychem Corporation | Medical devices incorporating SIM alloy elements |
US4484955A (en) | 1983-12-12 | 1984-11-27 | Hochstein Peter A | Shape memory material and method of treating same |
US4617932A (en) | 1984-04-25 | 1986-10-21 | Elliot Kornberg | Device and method for performing an intraluminal abdominal aortic aneurysm repair |
US4705507A (en) | 1984-05-02 | 1987-11-10 | Boyles Paul W | Arterial catheter means |
US4601309A (en) | 1985-04-23 | 1986-07-22 | The United States Of America As Represented By The United States Department Of Energy | Valve and dash-pot assembly |
JPS63238872A (en) | 1987-03-25 | 1988-10-04 | テルモ株式会社 | Instrument for securing inner diameter of cavity of tubular organ and catheter equipped therewith |
US4836204A (en) | 1987-07-06 | 1989-06-06 | Landymore Roderick W | Method for effecting closure of a perforation in the septum of the heart |
JPS6446477A (en) | 1987-08-13 | 1989-02-20 | Terumo Corp | Catheter |
US4979955A (en) | 1988-06-06 | 1990-12-25 | Smith Robert M | Power assisted prosthetic heart valve |
US4988339A (en) | 1988-12-30 | 1991-01-29 | Vadher Dinesh L | Retractable needle/syringe devices for blood collection, catheterization, and medicinal injection procedures |
US4995857A (en) | 1989-04-07 | 1991-02-26 | Arnold John R | Left ventricular assist device and method for temporary and permanent procedures |
US5186431A (en) | 1989-09-22 | 1993-02-16 | Yehuda Tamari | Pressure sensitive valves for extracorporeal circuits |
US5035706A (en) | 1989-10-17 | 1991-07-30 | Cook Incorporated | Percutaneous stent and method for retrieval thereof |
US5267940A (en) | 1989-11-29 | 1993-12-07 | The Administrators Of The Tulane Educational Fund | Cardiovascular flow enhancer and method of operation |
US5221261A (en) | 1990-04-12 | 1993-06-22 | Schneider (Usa) Inc. | Radially expandable fixation member |
US5035702A (en) | 1990-06-18 | 1991-07-30 | Taheri Syde A | Method and apparatus for providing an anastomosis |
US5234447A (en) | 1990-08-28 | 1993-08-10 | Robert L. Kaster | Side-to-end vascular anastomotic staple apparatus |
US5197978B1 (en) | 1991-04-26 | 1996-05-28 | Advanced Coronary Tech | Removable heat-recoverable tissue supporting device |
BR9206005A (en) | 1991-05-16 | 1994-08-02 | Mures Cardiovascular Research | Heart valve, process to form an artificial heart valve, flexible tissue for the formation of a heart valve, and, set to form trapezoidal pericardial membranes for the formation of a heart valve |
US5584803A (en) | 1991-07-16 | 1996-12-17 | Heartport, Inc. | System for cardiac procedures |
JP3393383B2 (en) | 1992-01-21 | 2003-04-07 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Septal defect closure device |
US5578008A (en) | 1992-04-22 | 1996-11-26 | Japan Crescent, Inc. | Heated balloon catheter |
WO1993022986A1 (en) | 1992-05-08 | 1993-11-25 | Schneider (Usa) Inc. | Esophageal stent and delivery tool |
US5332402A (en) | 1992-05-12 | 1994-07-26 | Teitelbaum George P | Percutaneously-inserted cardiac valve |
US5290227A (en) | 1992-08-06 | 1994-03-01 | Pasque Michael K | Method of implanting blood pump in ascending aorta or main pulmonary artery |
US5312341A (en) | 1992-08-14 | 1994-05-17 | Wayne State University | Retaining apparatus and procedure for transseptal catheterization |
US5409019A (en) | 1992-10-30 | 1995-04-25 | Wilk; Peter J. | Coronary artery by-pass method |
US5429144A (en) | 1992-10-30 | 1995-07-04 | Wilk; Peter J. | Coronary artery by-pass method |
US5326374A (en) | 1992-12-01 | 1994-07-05 | Michael N. Ilbawi | Body-implantable device for controlling the size of a fluid passageway |
US5713950A (en) | 1993-11-01 | 1998-02-03 | Cox; James L. | Method of replacing heart valves using flexible tubes |
US5531759A (en) | 1994-04-29 | 1996-07-02 | Kensey Nash Corporation | System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating |
US5597377A (en) | 1994-05-06 | 1997-01-28 | Trustees Of Boston University | Coronary sinus reperfusion catheter |
WO1995031945A1 (en) | 1994-05-19 | 1995-11-30 | Scimed Life Systems, Inc. | Improved tissue supporting devices |
ES2239322T3 (en) | 1994-06-27 | 2005-09-16 | Bard Peripheral Vascular, Inc. | RADIANTLY EXPANDABLE POLYETRAFLUORETILENE AND EXPANDABLE ENDOVASCULAR STENTS FORMED WITH THIS MATTER. |
US5725552A (en) | 1994-07-08 | 1998-03-10 | Aga Medical Corporation | Percutaneous catheter directed intravascular occlusion devices |
US5846261A (en) | 1994-07-08 | 1998-12-08 | Aga Medical Corp. | Percutaneous catheter directed occlusion devices |
US5545210A (en) | 1994-09-22 | 1996-08-13 | Advanced Coronary Technology, Inc. | Method of implanting a permanent shape memory alloy stent |
US5989244A (en) | 1994-11-15 | 1999-11-23 | Gregory; Kenton W. | Method of use of a sheet of elastin or elastin-based material |
NL9500147A (en) | 1995-01-26 | 1996-09-02 | Industrial Res Bv | A method of manufacturing a sheath-shaped stent from foil material and a stent obtained using this method. |
US5634936A (en) | 1995-02-06 | 1997-06-03 | Scimed Life Systems, Inc. | Device for closing a septal defect |
US5904697A (en) | 1995-02-24 | 1999-05-18 | Heartport, Inc. | Devices and methods for performing a vascular anastomosis |
US6264684B1 (en) | 1995-03-10 | 2001-07-24 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Helically supported graft |
US6451047B2 (en) | 1995-03-10 | 2002-09-17 | Impra, Inc. | Encapsulated intraluminal stent-graft and methods of making same |
US6039755A (en) | 1997-02-05 | 2000-03-21 | Impra, Inc., A Division Of C.R. Bard, Inc. | Radially expandable tubular polytetrafluoroethylene grafts and method of making same |
US6124523A (en) * | 1995-03-10 | 2000-09-26 | Impra, Inc. | Encapsulated stent |
US6579314B1 (en) | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
WO1996029957A1 (en) | 1995-03-29 | 1996-10-03 | CV DYNAMICS, INC., doing business as MEDICAL INCORPORATED | Bileaflet heart valve |
EP0819014B1 (en) | 1995-03-30 | 2003-02-05 | Heartport, Inc. | Endovascular cardiac venting catheter |
US5556386A (en) | 1995-04-03 | 1996-09-17 | Research Medical, Inc. | Medical pressure relief valve |
US6027518A (en) | 1995-05-30 | 2000-02-22 | Gaber; Benny | Seizing instrument |
US5662711A (en) | 1995-06-07 | 1997-09-02 | Douglas; William | Flow adjustable artery shunt |
US6214039B1 (en) | 1995-08-24 | 2001-04-10 | Impra, Inc., A Subsidiary Of C. R. Bard, Inc. | Covered endoluminal stent and method of assembly |
US6562052B2 (en) | 1995-08-24 | 2003-05-13 | Sutura, Inc. | Suturing device and method |
US6117144A (en) | 1995-08-24 | 2000-09-12 | Sutura, Inc. | Suturing device and method for sealing an opening in a blood vessel or other biological structure |
US5702412A (en) | 1995-10-03 | 1997-12-30 | Cedars-Sinai Medical Center | Method and devices for performing vascular anastomosis |
US5779716A (en) | 1995-10-06 | 1998-07-14 | Metamorphic Surgical Devices, Inc. | Device for removing solid objects from body canals, cavities and organs |
IL125416A0 (en) | 1996-02-02 | 1999-03-12 | Transvascular Inc | Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures |
US6039759A (en) | 1996-02-20 | 2000-03-21 | Baxter International Inc. | Mechanical prosthetic valve with coupled leaflets |
US5810836A (en) | 1996-03-04 | 1998-09-22 | Myocardial Stents, Inc. | Device and method for trans myocardial revascularization (TMR) |
US5853422A (en) | 1996-03-22 | 1998-12-29 | Scimed Life Systems, Inc. | Apparatus and method for closing a septal defect |
US6447539B1 (en) | 1996-09-16 | 2002-09-10 | Transvascular, Inc. | Method and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion |
US5655548A (en) | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US6086610A (en) | 1996-10-22 | 2000-07-11 | Nitinol Devices & Components | Composite self expanding stent device having a restraining element |
US6165188A (en) | 1996-12-02 | 2000-12-26 | Angiotrax, Inc. | Apparatus for percutaneously performing myocardial revascularization having controlled cutting depth and methods of use |
JP2001505807A (en) | 1996-12-10 | 2001-05-08 | パーデュー・リサーチ・ファウンデーション | Artificial vascular valve |
CN1626048B (en) | 1997-01-24 | 2012-09-12 | 帕拉贡知识产权有限责任公司 | Expandable device having bistable spring construction |
US6111520A (en) | 1997-04-18 | 2000-08-29 | Georgia Tech Research Corp. | System and method for the wireless sensing of physical properties |
US5795307A (en) | 1997-04-29 | 1998-08-18 | Krueger; John A. | Shunt tap apparatus and method |
US5957949A (en) | 1997-05-01 | 1999-09-28 | World Medical Manufacturing Corp. | Percutaneous placement valve stent |
JP2000514958A (en) | 1997-05-16 | 2000-11-07 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Silicon germanium semiconductor device and method of manufacturing the same |
JP3645399B2 (en) | 1997-06-09 | 2005-05-11 | 住友金属工業株式会社 | Endovascular stent |
US6120534A (en) | 1997-10-29 | 2000-09-19 | Ruiz; Carlos E. | Endoluminal prosthesis having adjustable constriction |
US5910144A (en) | 1998-01-09 | 1999-06-08 | Endovascular Technologies, Inc. | Prosthesis gripping system and method |
US6589198B1 (en) | 1998-01-29 | 2003-07-08 | David Soltanpour | Implantable micro-pump assembly |
AU1923999A (en) | 1998-01-30 | 1999-08-16 | Vascular Science Inc. | Medical graft connector or plug structures, and methods of making and installingsame |
US6638303B1 (en) | 1998-03-13 | 2003-10-28 | Carbomedics, Inc. | Heart valve prosthesis |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US6278379B1 (en) | 1998-04-02 | 2001-08-21 | Georgia Tech Research Corporation | System, method, and sensors for sensing physical properties |
US7083588B1 (en) | 1998-05-26 | 2006-08-01 | Medtronic Vascular, Inc. | Apparatus for providing coronary retroperfusion and methods of use |
US5941850A (en) | 1998-06-29 | 1999-08-24 | Shah; Binod | Safety cannula |
GB9816173D0 (en) | 1998-07-25 | 1998-09-23 | Huntleigh Technology Plc | Pneumatic systems |
US7169160B1 (en) | 1998-07-28 | 2007-01-30 | Medtronic, Inc. | Device for anchoring tubular element |
US6260552B1 (en) | 1998-07-29 | 2001-07-17 | Myocor, Inc. | Transventricular implant tools and devices |
US6406488B1 (en) | 1998-08-27 | 2002-06-18 | Heartstent Corporation | Healing transmyocardial implant |
US7118600B2 (en) * | 1998-08-31 | 2006-10-10 | Wilson-Cook Medical, Inc. | Prosthesis having a sleeve valve |
US6254564B1 (en) | 1998-09-10 | 2001-07-03 | Percardia, Inc. | Left ventricular conduit with blood vessel graft |
EP1112043B1 (en) | 1998-09-10 | 2006-04-05 | Percardia, Inc. | Tmr shunt |
US6641610B2 (en) | 1998-09-10 | 2003-11-04 | Percardia, Inc. | Valve designs for left ventricular conduits |
EP1726271B1 (en) | 1998-09-30 | 2012-07-25 | Bard Peripheral Vascular, Inc. | Selective adherence of stentgraft coverings, mandrel and method of making stent-graft device |
US6547814B2 (en) | 1998-09-30 | 2003-04-15 | Impra, Inc. | Selective adherence of stent-graft coverings |
US6217541B1 (en) | 1999-01-19 | 2001-04-17 | Kriton Medical, Inc. | Blood pump using cross-flow principles |
US6398803B1 (en) | 1999-02-02 | 2002-06-04 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Partial encapsulation of stents |
WO2000050100A1 (en) | 1999-02-26 | 2000-08-31 | Advanced Cardiovascular Systems, Inc. | Composite super elastic/shape memory alloy and malleable alloy stent |
US6210318B1 (en) | 1999-03-09 | 2001-04-03 | Abiomed, Inc. | Stented balloon pump system and method for using same |
US6695859B1 (en) | 1999-04-05 | 2004-02-24 | Coalescent Surgical, Inc. | Apparatus and methods for anastomosis |
US6287335B1 (en) | 1999-04-26 | 2001-09-11 | William J. Drasler | Intravascular folded tubular endoprosthesis |
US6712836B1 (en) | 1999-05-13 | 2004-03-30 | St. Jude Medical Atg, Inc. | Apparatus and methods for closing septal defects and occluding blood flow |
US6790229B1 (en) | 1999-05-25 | 2004-09-14 | Eric Berreklouw | Fixing device, in particular for fixing to vascular wall tissue |
US6344022B1 (en) | 1999-07-19 | 2002-02-05 | Robert Jarvik | Right ventricular bypass devices and methods of their use during heart surgery |
US6890350B1 (en) | 1999-07-28 | 2005-05-10 | Scimed Life Systems, Inc. | Combination self-expandable, balloon-expandable endoluminal device |
US6485507B1 (en) | 1999-07-28 | 2002-11-26 | Scimed Life Systems | Multi-property nitinol by heat treatment |
US7892246B2 (en) | 1999-07-28 | 2011-02-22 | Bioconnect Systems, Inc. | Devices and methods for interconnecting conduits and closing openings in tissue |
US6302892B1 (en) | 1999-08-04 | 2001-10-16 | Percardia, Inc. | Blood flow conduit delivery system and method of use |
WO2001010314A2 (en) | 1999-08-05 | 2001-02-15 | Broncus Technologies, Inc. | Methods and devices for creating collateral channels in the lungs |
US9694121B2 (en) | 1999-08-09 | 2017-07-04 | Cardiokinetix, Inc. | Systems and methods for improving cardiac function |
AU5812299A (en) | 1999-09-07 | 2001-04-10 | Microvena Corporation | Retrievable septal defect closure device |
US8579966B2 (en) | 1999-11-17 | 2013-11-12 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
US8016877B2 (en) | 1999-11-17 | 2011-09-13 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
US20070043435A1 (en) | 1999-11-17 | 2007-02-22 | Jacques Seguin | Non-cylindrical prosthetic valve system for transluminal delivery |
US6458153B1 (en) | 1999-12-31 | 2002-10-01 | Abps Venture One, Ltd. | Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof |
US6277078B1 (en) | 1999-11-19 | 2001-08-21 | Remon Medical Technologies, Ltd. | System and method for monitoring a parameter associated with the performance of a heart |
US6328699B1 (en) | 2000-01-11 | 2001-12-11 | Cedars-Sinai Medical Center | Permanently implantable system and method for detecting, diagnosing and treating congestive heart failure |
US8298150B2 (en) | 2000-01-11 | 2012-10-30 | Cedars-Sinai Medical Center | Hemodynamic waveform-based diagnosis and treatment |
US6970742B2 (en) | 2000-01-11 | 2005-11-29 | Savacor, Inc. | Method for detecting, diagnosing, and treating cardiovascular disease |
HUP0204398A2 (en) | 2000-01-27 | 2003-03-28 | 3F Therapeutics | Prosthetic heart valve |
US6475136B1 (en) | 2000-02-14 | 2002-11-05 | Obtech Medical Ag | Hydraulic heartburn and reflux treatment |
US6406422B1 (en) | 2000-03-02 | 2002-06-18 | Levram Medical Devices, Ltd. | Ventricular-assist method and apparatus |
US6468303B1 (en) | 2000-03-27 | 2002-10-22 | Aga Medical Corporation | Retrievable self expanding shunt |
US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US7056294B2 (en) | 2000-04-13 | 2006-06-06 | Ev3 Sunnyvale, Inc | Method and apparatus for accessing the left atrial appendage |
US8252044B1 (en) | 2000-11-17 | 2012-08-28 | Advanced Bio Prosthestic Surfaces, Ltd. | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US6527698B1 (en) | 2000-05-30 | 2003-03-04 | Abiomed, Inc. | Active left-right flow control in a two chamber cardiac prosthesis |
US6358277B1 (en) | 2000-06-21 | 2002-03-19 | The International Heart Institute Of Montana Foundation | Atrio-ventricular valvular device |
US6572652B2 (en) | 2000-08-29 | 2003-06-03 | Venpro Corporation | Method and devices for decreasing elevated pulmonary venous pressure |
AU1129902A (en) | 2000-09-29 | 2002-04-08 | Cordis Corp | Coated medical devices |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
MXPA03004395A (en) | 2000-11-22 | 2004-04-20 | Bard Peripheral Vascular Inc | High density microwall expanded polytetrafluoroethylene tubular structure. |
DE60115280T2 (en) | 2000-12-15 | 2006-08-10 | Angiomed Gmbh & Co. Medizintechnik Kg | STENT WITH HEARTLAP |
US6544208B2 (en) | 2000-12-29 | 2003-04-08 | C. Ross Ethier | Implantable shunt device |
US6802846B2 (en) | 2001-02-12 | 2004-10-12 | Ams Research Corporation | Foreign body retrieval device and method |
US6562066B1 (en) | 2001-03-02 | 2003-05-13 | Eric C. Martin | Stent for arterialization of the coronary sinus and retrograde perfusion of the myocardium |
US6632169B2 (en) | 2001-03-13 | 2003-10-14 | Ltk Enterprises, L.L.C. | Optimized pulsatile-flow ventricular-assist device and total artificial heart |
US8091556B2 (en) | 2001-04-20 | 2012-01-10 | V-Wave Ltd. | Methods and apparatus for reducing localized circulatory system pressure |
US20050148925A1 (en) | 2001-04-20 | 2005-07-07 | Dan Rottenberg | Device and method for controlling in-vivo pressure |
GB2378760A (en) | 2001-04-20 | 2003-02-19 | Marconi Medical Systems Uk Ltd | Surgical Probe |
JP2005506112A (en) | 2001-04-26 | 2005-03-03 | バスキュラー イノベイション,インコーポレイティド | Intraluminal device and method of making the same |
WO2002094363A2 (en) | 2001-05-21 | 2002-11-28 | Medtronic,Inc. | Trans-septal catheter with retention mechanism |
WO2002098296A1 (en) | 2001-06-05 | 2002-12-12 | Apex Medical, Inc. | Pressure sensing endograft |
US6685664B2 (en) | 2001-06-08 | 2004-02-03 | Chf Solutions, Inc. | Method and apparatus for ultrafiltration utilizing a long peripheral access venous cannula for blood withdrawal |
FR2827153A1 (en) | 2001-07-12 | 2003-01-17 | Younes Boudjemline | Closure for cardiopathic septal faults has hollow discoid body with central constriction forming tube with one way valve |
US7288105B2 (en) | 2001-08-01 | 2007-10-30 | Ev3 Endovascular, Inc. | Tissue opening occluder |
US20030036698A1 (en) | 2001-08-16 | 2003-02-20 | Robert Kohler | Interventional diagnostic catheter and a method for using a catheter to access artificial cardiac shunts |
US7842083B2 (en) | 2001-08-20 | 2010-11-30 | Innovational Holdings, Llc. | Expandable medical device with improved spatial distribution |
US6629988B2 (en) | 2001-08-28 | 2003-10-07 | Ethicon, Inc. | Composite staple for completing an anastomosis |
US20070129755A1 (en) | 2005-12-05 | 2007-06-07 | Ovalis, Inc. | Clip-based systems and methods for treating septal defects |
US20080015633A1 (en) | 2001-09-06 | 2008-01-17 | Ryan Abbott | Systems and Methods for Treating Septal Defects |
US20030176914A1 (en) | 2003-01-21 | 2003-09-18 | Rabkin Dmitry J. | Multi-segment modular stent and methods for manufacturing stents |
US6978176B2 (en) | 2001-12-08 | 2005-12-20 | Lattouf Omar M | Treatment for patient with congestive heart failure |
US7318833B2 (en) | 2001-12-19 | 2008-01-15 | Nmt Medical, Inc. | PFO closure device with flexible thrombogenic joint and improved dislodgement resistance |
ATE460902T1 (en) | 2001-12-20 | 2010-04-15 | Trivascular2 Inc | METHOD AND DEVICE FOR PRODUCING AN ENDOVASCULAR TRANSPLANT SECTION |
US20030139819A1 (en) | 2002-01-18 | 2003-07-24 | Beer Nicholas De | Method and apparatus for closing septal defects |
US7699059B2 (en) | 2002-01-22 | 2010-04-20 | Cardiomems, Inc. | Implantable wireless sensor |
US7311690B2 (en) | 2002-02-25 | 2007-12-25 | Novashunt Ag | Implantable fluid management system for the removal of excess fluid |
US6638257B2 (en) | 2002-03-01 | 2003-10-28 | Aga Medical Corporation | Intravascular flow restrictor |
US7270675B2 (en) | 2002-05-10 | 2007-09-18 | Cordis Corporation | Method of forming a tubular membrane on a structural frame |
US7862513B2 (en) | 2002-05-14 | 2011-01-04 | Pacesetter, Inc. | Apparatus for minimally invasive calibration of implanted pressure transducers |
US7621879B2 (en) | 2002-05-14 | 2009-11-24 | Pacesetter, Inc. | System for calibrating implanted sensors |
EP1538994A4 (en) | 2002-06-05 | 2008-05-07 | Nmt Medical Inc | Patent foramen ovale (pfo) closure device with radial and circumferential support |
US7390310B2 (en) | 2002-07-10 | 2008-06-24 | Codman & Shurtleff, Inc. | Shunt valve locking mechanism |
TW547058U (en) | 2002-07-23 | 2003-08-11 | Nien Made Entpr Co Ltd | Sectional curtain |
US7025777B2 (en) | 2002-07-31 | 2006-04-11 | Unison Therapeutics, Inc. | Flexible and conformable stent and method of forming same |
US7147604B1 (en) | 2002-08-07 | 2006-12-12 | Cardiomems, Inc. | High Q factor sensor |
EP1549394B1 (en) | 2002-09-26 | 2011-12-07 | Pacesetter, Inc. | Cardiovascular anchoring device |
US8303511B2 (en) | 2002-09-26 | 2012-11-06 | Pacesetter, Inc. | Implantable pressure transducer system optimized for reduced thrombosis effect |
US7615010B1 (en) | 2002-10-03 | 2009-11-10 | Integrated Sensing Systems, Inc. | System for monitoring the physiologic parameters of patients with congestive heart failure |
US7169172B2 (en) | 2002-11-01 | 2007-01-30 | Counter Clockwise, Inc. | Method and apparatus for caged stent delivery |
US7608067B2 (en) | 2002-11-06 | 2009-10-27 | Aram Bonni | Patient-adjustable incontinence device (AID) |
US7404824B1 (en) | 2002-11-15 | 2008-07-29 | Advanced Cardiovascular Systems, Inc. | Valve aptation assist device |
US6923829B2 (en) | 2002-11-25 | 2005-08-02 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable expandable medical devices having regions of differential mechanical properties and methods of making same |
US20040162514A1 (en) | 2003-02-14 | 2004-08-19 | Scout Medical Technologies | System and method for controlling differential pressure in a cardio-vascular system |
EP1603492B1 (en) | 2003-03-12 | 2009-12-23 | Cook Incorporated | Prosthetic valve that permits retrograde flow |
WO2004082528A2 (en) | 2003-03-17 | 2004-09-30 | Cook Incorporated | Vascular valve with removable support component |
US7967769B2 (en) | 2003-04-08 | 2011-06-28 | Rox Medical Inc. | Implantable arterio-venous shunt devices and methods for their use |
US8372112B2 (en) | 2003-04-11 | 2013-02-12 | St. Jude Medical, Cardiology Division, Inc. | Closure devices, related delivery methods, and related methods of use |
US20040267306A1 (en) | 2003-04-11 | 2004-12-30 | Velocimed, L.L.C. | Closure devices, related delivery methods, and related methods of use |
US7175656B2 (en) | 2003-04-18 | 2007-02-13 | Alexander Khairkhahan | Percutaneous transcatheter heart valve replacement |
US20050003327A1 (en) | 2003-05-12 | 2005-01-06 | Nicolas Elian | Drilling system and method for dental implants |
US20030216803A1 (en) | 2003-05-28 | 2003-11-20 | Ledergerber Walter J. | Textured and drug eluting stent-grafts |
US7041127B2 (en) | 2003-05-28 | 2006-05-09 | Ledergerber Walter J | Textured and drug eluting coronary artery stent |
US7317951B2 (en) | 2003-07-25 | 2008-01-08 | Integrated Sensing Systems, Inc. | Anchor for medical implant placement and method of manufacture |
US7245117B1 (en) | 2004-11-01 | 2007-07-17 | Cardiomems, Inc. | Communicating with implanted wireless sensor |
JP2007527272A (en) | 2003-10-10 | 2007-09-27 | コヒーレックス メディカル インコーポレイテッド | Patent foramen ovale (PFO) closure device, delivery device, and related methods and systems |
IL158960A0 (en) | 2003-11-19 | 2004-05-12 | Neovasc Medical Ltd | Vascular implant |
US20050165344A1 (en) | 2003-11-26 | 2005-07-28 | Dobak John D.Iii | Method and apparatus for treating heart failure |
US7261732B2 (en) | 2003-12-22 | 2007-08-28 | Henri Justino | Stent mounted valve |
US7780725B2 (en) | 2004-06-16 | 2010-08-24 | Sadra Medical, Inc. | Everting heart valve |
US8603160B2 (en) | 2003-12-23 | 2013-12-10 | Sadra Medical, Inc. | Method of using a retrievable heart valve anchor with a sheath |
US7988724B2 (en) | 2003-12-23 | 2011-08-02 | Sadra Medical, Inc. | Systems and methods for delivering a medical implant |
US7311730B2 (en) | 2004-02-13 | 2007-12-25 | Shlomo Gabbay | Support apparatus and heart valve prosthesis for sutureless implantation |
US20050267524A1 (en) | 2004-04-09 | 2005-12-01 | Nmt Medical, Inc. | Split ends closure device |
EP1753374A4 (en) | 2004-04-23 | 2010-02-10 | 3F Therapeutics Inc | Implantable prosthetic valve |
US7704268B2 (en) | 2004-05-07 | 2010-04-27 | Nmt Medical, Inc. | Closure device with hinges |
US7842069B2 (en) | 2004-05-07 | 2010-11-30 | Nmt Medical, Inc. | Inflatable occluder |
EP1604697A1 (en) | 2004-06-09 | 2005-12-14 | J.A.C.C. GmbH | Implantable device |
US8313524B2 (en) | 2004-08-31 | 2012-11-20 | C. R. Bard, Inc. | Self-sealing PTFE graft with kink resistance |
US8764848B2 (en) | 2004-09-24 | 2014-07-01 | W.L. Gore & Associates, Inc. | Occluder device double securement system for delivery/recovery of such occluder device |
US7993383B2 (en) | 2004-09-28 | 2011-08-09 | William A. Cook Australia Pty. Ltd. | Device for treating aortic dissection |
US7794473B2 (en) | 2004-11-12 | 2010-09-14 | C.R. Bard, Inc. | Filter delivery system |
US7905901B2 (en) | 2004-11-29 | 2011-03-15 | Cardia, Inc. | Self-centering occlusion device |
US20060122522A1 (en) | 2004-12-03 | 2006-06-08 | Abhi Chavan | Devices and methods for positioning and anchoring implantable sensor devices |
US7524329B2 (en) | 2005-02-08 | 2009-04-28 | Wilson-Cook Medical Inc. | Self contracting stent |
US20060174712A1 (en) | 2005-02-10 | 2006-08-10 | Cardiomems, Inc. | Hermetic chamber with electrical feedthroughs |
CA2599965C (en) | 2005-03-04 | 2014-05-06 | Cardiomems, Inc. | Communicating with an implanted wireless sensor |
US8025625B2 (en) | 2005-04-12 | 2011-09-27 | Cardiomems, Inc. | Sensor with electromagnetically coupled hermetic pressure reference |
SE531468C2 (en) | 2005-04-21 | 2009-04-14 | Edwards Lifesciences Ag | An apparatus for controlling blood flow |
US8025668B2 (en) | 2005-04-28 | 2011-09-27 | C. R. Bard, Inc. | Medical device removal system |
US7376006B2 (en) | 2005-05-13 | 2008-05-20 | International Business Machines Corporation | Enhanced programming performance in a nonvolatile memory device having a bipolar programmable storage element |
US8012198B2 (en) | 2005-06-10 | 2011-09-06 | Boston Scientific Scimed, Inc. | Venous valve, system, and method |
JP2009501027A (en) | 2005-06-17 | 2009-01-15 | シー・アール・バード・インコーポレイテツド | Vascular graft with kinking resistance after tightening |
US20070021739A1 (en) | 2005-07-24 | 2007-01-25 | Lascor Gmbh | Inter-atrial Transseptal Laser Puncture (TLP) Procedure |
US8167932B2 (en) | 2005-10-18 | 2012-05-01 | Edwards Lifesciences Corporation | Heart valve delivery system with valve catheter |
DE102005056532A1 (en) | 2005-11-28 | 2007-05-31 | Mnemoscience Gmbh | Method for removal of tubular tissue supports e.g. stents from human or animal hollow organs, involves heating of tissue support to temperature below transition temperature, till softening |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
US8834912B2 (en) | 2005-12-30 | 2014-09-16 | Boston Scientific Scimed, Inc. | Medical devices having multiple charged layers |
EP1979023B1 (en) | 2006-01-17 | 2015-07-22 | Transcend Medical, Inc. | Glaucoma treatment device |
US9681948B2 (en) | 2006-01-23 | 2017-06-20 | V-Wave Ltd. | Heart anchor device |
US20110022057A1 (en) | 2006-02-03 | 2011-01-27 | Pacesetter, Inc. | Apparatus and methods for transferring an implanted elongate body to a remote site |
US7402899B1 (en) | 2006-02-03 | 2008-07-22 | Pacesetter, Inc. | Hermetically sealable silicon system and method of making same |
US8235916B2 (en) | 2006-02-03 | 2012-08-07 | Pacesetter, Inc. | System and method for manipulating insertion pathways for accessing target sites |
CA2643720A1 (en) * | 2006-02-28 | 2007-09-07 | Debra A. Bebb | Flexible stretch stent-graft |
EP1849440A1 (en) | 2006-04-28 | 2007-10-31 | Younes Boudjemline | Vascular stents with varying diameter |
ATE543267T1 (en) | 2006-09-08 | 2012-02-15 | Cardiomems Inc | SYSTEM FOR COLLECTION AND MANAGEMENT OF PHYSIOLOGICAL DATA FOR USE IN AN IMPLANTED RADIO SENSOR |
US8876894B2 (en) | 2006-09-19 | 2014-11-04 | Medtronic Ventor Technologies Ltd. | Leaflet-sensitive valve fixation member |
JP2010505597A (en) | 2006-10-10 | 2010-02-25 | セロノバ バイオサイエンシーズ, インコーポレイテッド | Bioprosthetic heart valve using polyphosphazene |
US20080269774A1 (en) | 2006-10-26 | 2008-10-30 | Chestnut Medical Technologies, Inc. | Intracorporeal Grasping Device |
US9232997B2 (en) | 2006-11-07 | 2016-01-12 | Corvia Medical, Inc. | Devices and methods for retrievable intra-atrial implants |
US8745845B2 (en) | 2006-11-07 | 2014-06-10 | Dc Devices, Inc. | Methods for mounting a prosthesis onto a delivery device |
US20110257723A1 (en) | 2006-11-07 | 2011-10-20 | Dc Devices, Inc. | Devices and methods for coronary sinus pressure relief |
US10413284B2 (en) | 2006-11-07 | 2019-09-17 | Corvia Medical, Inc. | Atrial pressure regulation with control, sensing, monitoring and therapy delivery |
US10624621B2 (en) | 2006-11-07 | 2020-04-21 | Corvia Medical, Inc. | Devices and methods for the treatment of heart failure |
US8460372B2 (en) | 2006-11-07 | 2013-06-11 | Dc Devices, Inc. | Prosthesis for reducing intra-cardiac pressure having an embolic filter |
US8882697B2 (en) | 2006-11-07 | 2014-11-11 | Dc Devices, Inc. | Apparatus and methods to create and maintain an intra-atrial pressure relief opening |
US7552853B2 (en) | 2007-01-24 | 2009-06-30 | Medtronic Vascular, Inc. | Low-profile vascular closure systems and methods of using same |
US9504568B2 (en) | 2007-02-16 | 2016-11-29 | Medtronic, Inc. | Replacement prosthetic heart valves and methods of implantation |
CN101842061A (en) | 2007-06-25 | 2010-09-22 | 微排放器公司 | Self-expanding prosthesis |
EP2420205B1 (en) | 2007-06-26 | 2014-04-09 | St. Jude Medical, Inc. | Apparatus for implanting collapsible/expandable prosthetic heart valves |
US8147545B2 (en) | 2007-06-26 | 2012-04-03 | Galit Avior | Eustachian tube device |
US8142363B1 (en) | 2007-07-11 | 2012-03-27 | Pacesetter, Inc. | Cardiac rhythm management lead with omni-directional pressure sensing |
US9566178B2 (en) | 2010-06-24 | 2017-02-14 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
US8192351B2 (en) | 2007-08-13 | 2012-06-05 | Paracor Medical, Inc. | Medical device delivery system having integrated introducer |
US8747458B2 (en) | 2007-08-20 | 2014-06-10 | Medtronic Ventor Technologies Ltd. | Stent loading tool and method for use thereof |
US8734483B2 (en) | 2007-08-27 | 2014-05-27 | Cook Medical Technologies Llc | Spider PFO closure device |
WO2009052188A1 (en) | 2007-10-15 | 2009-04-23 | Edwards Lifesciences Corporation | Transcatheter heart valve with micro-anchors |
BRPI0819217B8 (en) | 2007-10-25 | 2021-06-22 | Symetis Sa | replacement valve for use within a human body, system for replacing a valve within a human body, and heart valve release system with stent |
US7806921B2 (en) | 2007-11-08 | 2010-10-05 | Cook Incorporated | Monocusp valve design |
US9393115B2 (en) | 2008-01-24 | 2016-07-19 | Medtronic, Inc. | Delivery systems and methods of implantation for prosthetic heart valves |
US8157853B2 (en) | 2008-01-24 | 2012-04-17 | Medtronic, Inc. | Delivery systems and methods of implantation for prosthetic heart valves |
US9138213B2 (en) | 2008-03-07 | 2015-09-22 | W.L. Gore & Associates, Inc. | Heart occlusion devices |
US20130165967A1 (en) | 2008-03-07 | 2013-06-27 | W.L. Gore & Associates, Inc. | Heart occlusion devices |
US20090276040A1 (en) | 2008-05-01 | 2009-11-05 | Edwards Lifesciences Corporation | Device and method for replacing mitral valve |
US8323335B2 (en) | 2008-06-20 | 2012-12-04 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves and methods for using |
US20100022940A1 (en) | 2008-07-25 | 2010-01-28 | Medtronic Vascular, Inc. | Percutaneously Introduceable Shunt Devices and Methods |
US8652202B2 (en) | 2008-08-22 | 2014-02-18 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
JP2012501806A (en) | 2008-09-12 | 2012-01-26 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Stent layer manufacturing of stents |
JP4649506B2 (en) | 2008-09-16 | 2011-03-09 | 有限会社日本エレクテル | High frequency heating balloon catheter |
EP2340075B1 (en) | 2008-10-10 | 2013-03-06 | Sadra Medical, Inc. | Medical devices and delivery systems for delivering medical devices |
US8986361B2 (en) | 2008-10-17 | 2015-03-24 | Medtronic Corevalve, Inc. | Delivery system for deployment of medical devices |
US9089311B2 (en) | 2009-01-09 | 2015-07-28 | Abbott Vascular Inc. | Vessel closure devices and methods |
US8021420B2 (en) | 2009-03-12 | 2011-09-20 | Medtronic Vascular, Inc. | Prosthetic valve delivery system |
CN101919752B (en) | 2009-03-30 | 2014-04-09 | 苏州杰成医疗科技有限公司 | Valve prosthesis with movably attached claspers with apex |
US8257251B2 (en) | 2009-04-08 | 2012-09-04 | Ethicon Endo-Surgery, Inc. | Methods and devices for providing access into a body cavity |
US8414644B2 (en) | 2009-04-15 | 2013-04-09 | Cardiaq Valve Technologies, Inc. | Vascular implant and delivery system |
CA2760207C (en) | 2009-04-28 | 2014-08-12 | Dc Devices, Inc. | Devices, systems and methods to treat heart failure |
US10076403B1 (en) | 2009-05-04 | 2018-09-18 | V-Wave Ltd. | Shunt for redistributing atrial blood volume |
EP2427143B1 (en) | 2009-05-04 | 2017-08-02 | V-Wave Ltd. | Device for regulating pressure in a heart chamber |
US9034034B2 (en) | 2010-12-22 | 2015-05-19 | V-Wave Ltd. | Devices for reducing left atrial pressure, and methods of making and using same |
US20100292779A1 (en) | 2009-05-15 | 2010-11-18 | Helmut Straubinger | Device for compressing a stent and a system as well as a method for loading a stent into a medical delivery system |
JP5535313B2 (en) | 2009-05-29 | 2014-07-02 | エックスルミナ, インコーポレイテッド | Device and method for deploying a stent across adjacent tissue layers |
US20120083832A1 (en) | 2009-06-03 | 2012-04-05 | Symetis Sa | Closure device and methods and systems for using same |
US8956389B2 (en) | 2009-06-22 | 2015-02-17 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
JP6245805B2 (en) | 2009-08-07 | 2017-12-13 | スマーター アロイズ インコーポレーテッド | Shape memory material processing method and shape memory material processing apparatus |
US20110054515A1 (en) | 2009-08-25 | 2011-03-03 | John Bridgeman | Device and method for occluding the left atrial appendage |
US9757107B2 (en) | 2009-09-04 | 2017-09-12 | Corvia Medical, Inc. | Methods and devices for intra-atrial shunts having adjustable sizes |
US9642993B2 (en) | 2011-12-22 | 2017-05-09 | Corvia Medical, Inc. | Methods and devices for intra-atrial shunts having selectable flow rates |
WO2011037866A1 (en) | 2009-09-22 | 2011-03-31 | Cook Incorporated | Vessel closure device |
US8114149B2 (en) | 2009-10-20 | 2012-02-14 | Svelte Medical Systems, Inc. | Hybrid stent with helical connectors |
US9011520B2 (en) | 2009-10-29 | 2015-04-21 | Valtech Cardio, Ltd. | Tissue anchor for annuloplasty device |
AU2010311811B2 (en) | 2009-11-02 | 2015-09-17 | Symetis Sa | Aortic bioprosthesis and systems for delivery thereof |
US9757263B2 (en) | 2009-11-18 | 2017-09-12 | Cook Medical Technologies Llc | Stent graft and introducer assembly |
US8715300B2 (en) | 2009-12-05 | 2014-05-06 | Integrated Sensing Systems, Inc. | Delivery system, method, and anchor for medical implant placement |
US20110152923A1 (en) | 2009-12-18 | 2011-06-23 | Ethicon Endo-Surgery, Inc. | Incision closure device |
CA2785041A1 (en) | 2010-01-29 | 2011-08-04 | Dc Devices, Inc. | Devices and methods for reducing venous pressure |
PL3335670T3 (en) | 2010-03-05 | 2022-09-05 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves |
US8512401B2 (en) | 2010-04-12 | 2013-08-20 | Medtronic, Inc. | Transcatheter prosthetic heart valve delivery system with funnel recapturing feature and method |
US8524132B2 (en) * | 2010-04-14 | 2013-09-03 | Abbott Cardiovascular Systems Inc. | Method of fabricating an intraluminal scaffold with an enlarged portion |
WO2011139746A1 (en) | 2010-04-27 | 2011-11-10 | Medtronic Inc. | Transcatheter prosthetic heart valve delivery device with passive trigger release |
US8419767B2 (en) | 2010-05-04 | 2013-04-16 | Mustafa H. Al-Qbandi | Steerable atrial septal occluder implantation device with flexible neck |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
EP2387951B1 (en) | 2010-05-23 | 2012-12-26 | Occlutech Holding AG | Braided medical device and manufacturing method therefore |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
EP4098227A1 (en) | 2010-07-23 | 2022-12-07 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves |
US8597225B2 (en) | 2010-07-26 | 2013-12-03 | The Cleveland Clinic Foundation | Method for increasing blood flow in or about a cardiac or other vascular or prosthetic structure to prevent thrombosis |
US20120046528A1 (en) | 2010-08-17 | 2012-02-23 | Pacesetter, Inc. | System and method for detecting and treating cardiovascular disease |
US20120190991A1 (en) | 2011-01-24 | 2012-07-26 | Pacesetter, Inc. | System and Method for Detecting a Clinically-Significant Pulmonary Fluid Accumulation Using an Implantable Medical Device |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9522064B2 (en) | 2011-05-16 | 2016-12-20 | Hlt, Inc. | Inversion delivery device and method for a prosthesis |
WO2012175483A1 (en) | 2011-06-20 | 2012-12-27 | Jacques Seguin | Prosthetic leaflet assembly for repairing a defective cardiac valve and methods of using the same |
US9629715B2 (en) | 2011-07-28 | 2017-04-25 | V-Wave Ltd. | Devices for reducing left atrial pressure having biodegradable constriction, and methods of making and using same |
US11135054B2 (en) | 2011-07-28 | 2021-10-05 | V-Wave Ltd. | Interatrial shunts having biodegradable material, and methods of making and using same |
EP2755562B8 (en) | 2011-09-12 | 2017-01-25 | Highlife SAS | Treatment catheter system |
CN102462565B (en) | 2011-10-25 | 2014-03-26 | 张石江 | Recyclable and adjustable interventional stent for constricting blood vessels |
US8845684B2 (en) | 2011-11-30 | 2014-09-30 | Abbott Cardiovascular Systems, Inc. | Tissue closure device with resilient arms |
US20140350669A1 (en) | 2011-12-01 | 2014-11-27 | The Trustees if The University of Pennsylvania | Percutaneous valve replacement devices |
EP2785277B1 (en) * | 2011-12-04 | 2017-04-05 | Endospan Ltd. | Branched stent-graft system |
US8894701B2 (en) | 2011-12-23 | 2014-11-25 | Cook Medical Technologies Llc | Hybrid balloon-expandable/self-expanding prosthesis for deployment in a body vessel and method of making |
JP2013153810A (en) | 2012-01-27 | 2013-08-15 | Terumo Corp | Knob treatment device and knob treatment method |
US9005155B2 (en) | 2012-02-03 | 2015-04-14 | Dc Devices, Inc. | Devices and methods for treating heart failure |
WO2013119630A1 (en) | 2012-02-06 | 2013-08-15 | Cook Medical Technologies Llc | Artificial device deployment apparatus |
US8882798B2 (en) | 2012-02-13 | 2014-11-11 | Apollo Endosurgery, Inc. | Endoscopic tools for the removal of balloon-like intragastric devices |
US9067050B2 (en) | 2012-03-30 | 2015-06-30 | Medtronic Vascular, Inc. | Arteriovenous shunt having a flow control mechanism |
US10588611B2 (en) | 2012-04-19 | 2020-03-17 | Corvia Medical Inc. | Implant retention attachment and method of use |
CA2873440C (en) * | 2012-05-14 | 2020-06-02 | C.R. Bard, Inc. | Uniformly expandable stent |
WO2013175468A2 (en) | 2012-05-20 | 2013-11-28 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Prosthetic mitral valve |
US9649480B2 (en) | 2012-07-06 | 2017-05-16 | Corvia Medical, Inc. | Devices and methods of treating or ameliorating diastolic heart failure through pulmonary valve intervention |
CN104508864B (en) | 2012-07-30 | 2017-04-19 | 帝人株式会社 | Non-aqueous electrolyte battery separator and non-aqueous electrolyte battery |
US9649212B2 (en) | 2012-08-30 | 2017-05-16 | Biotronik Ag | Release device for releasing a medical implant from a catheter and catheter comprising a release device |
US9023099B2 (en) | 2012-10-31 | 2015-05-05 | Medtronic Vascular Galway Limited | Prosthetic mitral valve and delivery method |
EP2922592B1 (en) | 2012-11-21 | 2022-09-21 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic heart valves |
US10098551B2 (en) | 2013-01-31 | 2018-10-16 | Pacesetter, Inc. | Wireless MEMS left atrial pressure sensor |
US10413401B2 (en) * | 2013-02-01 | 2019-09-17 | Medtronic CV Luxembourg S.a.r.l. | Anti-paravalvular leakage component for a transcatheter valve prosthesis |
US9844435B2 (en) | 2013-03-01 | 2017-12-19 | St. Jude Medical, Cardiology Division, Inc. | Transapical mitral valve replacement |
US9775636B2 (en) | 2013-03-12 | 2017-10-03 | Corvia Medical, Inc. | Devices, systems, and methods for treating heart failure |
US9867697B2 (en) | 2013-03-12 | 2018-01-16 | St. Jude Medical, Cardiology Division, Inc. | Self-actuating sealing portions for a paravalvular leak protection |
US20140277054A1 (en) | 2013-03-15 | 2014-09-18 | Dc Devices, Inc. | Devices, systems, and methods for percutaneous trans-septal puncture |
US9220429B2 (en) | 2013-03-15 | 2015-12-29 | Pacesetter, Inc. | Systems and methods to determine HR, RR and classify cardiac rhythms based on atrial IEGM and atrial pressure signals |
US10105103B2 (en) | 2013-04-18 | 2018-10-23 | Vectorious Medical Technologies Ltd. | Remotely powered sensory implant |
EP2999412B1 (en) | 2013-05-21 | 2020-05-06 | V-Wave Ltd. | Apparatus for delivering devices for reducing left atrial pressure |
WO2014197498A1 (en) | 2013-06-04 | 2014-12-11 | Boston Scientific Scimed, Inc. | Tissue spreader for accessing papilla, and related methods of use |
US11911258B2 (en) | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
US10195028B2 (en) | 2013-09-10 | 2019-02-05 | Edwards Lifesciences Corporation | Magnetic retaining mechanisms for prosthetic valves |
US10123870B2 (en) | 2013-09-12 | 2018-11-13 | St. Jude Medical, Cardiology Division, Inc. | Alignment of an implantable medical device |
WO2015057838A1 (en) | 2013-10-15 | 2015-04-23 | Boston Scientific Scimed, Inc. | Methods and systems for loading and delivering a stent |
US20150112383A1 (en) | 2013-10-21 | 2015-04-23 | Cook Medical Technologies Llc | Closure device |
US20150119796A1 (en) | 2013-10-26 | 2015-04-30 | Dc Devices, Inc. | Anti-Lockup Thread Attachment Mechanism and Method of Use Thereof |
US9775591B2 (en) | 2013-11-21 | 2017-10-03 | Edwards Lifesciences Corporation | Sealing devices and related delivery apparatuses |
US9622863B2 (en) | 2013-11-22 | 2017-04-18 | Edwards Lifesciences Corporation | Aortic insufficiency repair device and method |
US10098734B2 (en) | 2013-12-05 | 2018-10-16 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
US9907641B2 (en) * | 2014-01-10 | 2018-03-06 | W. L. Gore & Associates, Inc. | Implantable intraluminal device |
WO2015112494A1 (en) | 2014-01-23 | 2015-07-30 | St. Jude Medical, Cardiology Division, Inc. | Medical devices including high strength bond joints and methods of making same |
US10675450B2 (en) | 2014-03-12 | 2020-06-09 | Corvia Medical, Inc. | Devices and methods for treating heart failure |
US10149758B2 (en) | 2014-04-01 | 2018-12-11 | Medtronic, Inc. | System and method of stepped deployment of prosthetic heart valve |
WO2015157116A1 (en) | 2014-04-08 | 2015-10-15 | Boston Scientific Scimed, Inc. | Endoscopic closure device |
US11712230B2 (en) | 2014-05-02 | 2023-08-01 | W. L. Gore & Associates, Inc. | Occluder and anastomosis devices |
US9814483B2 (en) | 2014-06-13 | 2017-11-14 | InterShunt Technologies, Inc. | Method and catheter for creating an interatrial aperture |
JP2017527694A (en) | 2014-07-14 | 2017-09-21 | スマーター アロイズ インコーポレーテッド | Double memory material, system, method and application |
CA2955389C (en) | 2014-07-23 | 2023-04-04 | Corvia Medical, Inc. | Devices and methods for treating heart failure |
WO2016030767A1 (en) | 2014-08-27 | 2016-03-03 | Distalmotion Sa | Surgical system for microsurgical techniques |
EP3193791B1 (en) | 2014-09-09 | 2018-08-22 | Occlutech Holding AG | A flow regulating device in the heart |
US10111741B2 (en) | 2014-10-29 | 2018-10-30 | W. L. Gore & Associates, Inc. | Intralumenal stent graft fixation |
US10932786B2 (en) | 2014-11-04 | 2021-03-02 | Corvia Medical, Inc. | Devices and methods for treating patent ductus arteriosus |
CN111437068B (en) | 2014-12-04 | 2023-01-17 | 爱德华兹生命科学公司 | Percutaneous clamp for repairing heart valve |
WO2016115375A1 (en) | 2015-01-16 | 2016-07-21 | Boston Scientific Scimed, Inc. | Displacement based lock and release mechanism |
US9861477B2 (en) | 2015-01-26 | 2018-01-09 | Boston Scientific Scimed Inc. | Prosthetic heart valve square leaflet-leaflet stitch |
US10201417B2 (en) | 2015-02-03 | 2019-02-12 | Boston Scientific Scimed Inc. | Prosthetic heart valve having tubular seal |
US9788942B2 (en) | 2015-02-03 | 2017-10-17 | Boston Scientific Scimed Inc. | Prosthetic heart valve having tubular seal |
US10080652B2 (en) | 2015-03-13 | 2018-09-25 | Boston Scientific Scimed, Inc. | Prosthetic heart valve having an improved tubular seal |
US20170224444A1 (en) | 2015-04-06 | 2017-08-10 | Smarter Alloys Inc. | Systems and methods for orthodontic archwires for malocclusions |
US10426609B2 (en) | 2015-04-09 | 2019-10-01 | Boston Scientific Scimed, Inc. | Fiber reinforced prosthetic heart valve having undulating fibers |
US10940296B2 (en) | 2015-05-07 | 2021-03-09 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Temporary interatrial shunts |
US9789294B2 (en) | 2015-10-07 | 2017-10-17 | Edwards Lifesciences Corporation | Expandable cardiac shunt |
US10463477B2 (en) | 2015-11-09 | 2019-11-05 | Corvia Medical, Inc. | Retrievable devices for treating heart failure |
US10265169B2 (en) | 2015-11-23 | 2019-04-23 | Edwards Lifesciences Corporation | Apparatus for controlled heart valve delivery |
WO2017118920A1 (en) | 2016-01-04 | 2017-07-13 | Cardiopass Ltd. | Cutting device with expandable anvil |
US10265059B2 (en) | 2016-02-04 | 2019-04-23 | Edwards Lifesciences Corporation | Trans-septal closure and port device |
US10531866B2 (en) | 2016-02-16 | 2020-01-14 | Cardiovalve Ltd. | Techniques for providing a replacement valve and transseptal communication |
US10207807B2 (en) | 2016-04-13 | 2019-02-19 | The Boeing Company | Condensate removal system of an aircraft cooling system |
US20170340460A1 (en) | 2016-05-31 | 2017-11-30 | V-Wave Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US10835394B2 (en) | 2016-05-31 | 2020-11-17 | V-Wave, Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US10531941B2 (en) | 2016-11-09 | 2020-01-14 | Boston Scientific Scimed, Inc. | Stent including anti-migration capabilities |
EP3568089B1 (en) | 2017-01-11 | 2021-09-15 | Virender K. Sharma | Cardiac shunt device and delivery system |
US11135410B2 (en) | 2017-02-26 | 2021-10-05 | Corvia Medical, Inc. | Devices and methods for treating heart failure |
US11291807B2 (en) | 2017-03-03 | 2022-04-05 | V-Wave Ltd. | Asymmetric shunt for redistributing atrial blood volume |
AU2018228451B2 (en) | 2017-03-03 | 2022-12-08 | V-Wave Ltd. | Shunt for redistributing atrial blood volume |
WO2018220589A1 (en) | 2017-06-02 | 2018-12-06 | HemoDynamx Technologies, Ltd. | Flow modification in body lumens |
CN209059540U (en) | 2017-07-18 | 2019-07-05 | 杭州诺生医疗科技有限公司 | Interatrial pressure-regulating device |
EP3705154A4 (en) | 2017-10-31 | 2020-12-23 | Hangzhou Noya Medtech Co., Ltd | Atrial septostomy device, atrial septostomy system, operating method for same, and opening-creation method |
CN111432743A (en) | 2017-11-30 | 2020-07-17 | 阿列维安特医疗公司 | Transcatheter device for atrioventricular anastomosis |
US11744589B2 (en) | 2018-01-20 | 2023-09-05 | V-Wave Ltd. | Devices and methods for providing passage between heart chambers |
US10898698B1 (en) | 2020-05-04 | 2021-01-26 | V-Wave Ltd. | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same |
WO2019179447A1 (en) | 2018-03-19 | 2019-09-26 | 杭州诺生医疗科技有限公司 | Transcatheter interventional atrial septostomy device |
EP3794260A4 (en) | 2018-05-16 | 2022-06-22 | Smarter Alloys Inc. | Shape memory alloy valve and method for fabrication thereof |
JP2022501113A (en) | 2018-09-19 | 2022-01-06 | エヌエックスティー バイオメディカル, エルエルシーNxt Biomedical, Llc | Methods and techniques for forming connections and shunts between cavities and tubes of biological structure |
AU2019404588B2 (en) | 2018-12-21 | 2022-12-15 | W. L. Gore & Associates, Inc. | Implantable medical device with adjustable blood flow |
US11612385B2 (en) | 2019-04-03 | 2023-03-28 | V-Wave Ltd. | Systems and methods for delivering implantable devices across an atrial septum |
US11865282B2 (en) | 2019-05-20 | 2024-01-09 | V-Wave Ltd. | Systems and methods for creating an interatrial shunt |
CN114667117A (en) | 2019-09-09 | 2022-06-24 | 施菲姆德控股有限责任公司 | Adjustable flow splitters and associated systems and methods |
US11234702B1 (en) | 2020-11-13 | 2022-02-01 | V-Wave Ltd. | Interatrial shunt having physiologic sensor |
-
2017
- 2017-05-30 US US15/608,948 patent/US20170340460A1/en not_active Abandoned
- 2017-10-30 US US15/798,250 patent/US11109988B2/en active Active
-
2021
- 2021-09-02 US US17/465,791 patent/US11497631B2/en active Active
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11382747B2 (en) | 2004-02-03 | 2022-07-12 | V-Wave, Ltd. | Device and method for controlling in-vivo pressure |
US11253353B2 (en) | 2006-01-23 | 2022-02-22 | V-Wave Ltd. | Heart anchor device |
US11850138B2 (en) | 2009-05-04 | 2023-12-26 | V-Wave Ltd. | Shunt for redistributing atrial blood volume |
US11723765B2 (en) * | 2010-03-26 | 2023-08-15 | Thubrikar Aortic Valve, Inc. | Valve component, frame component and prosthetic valve device including the same for implantation in a body lumen |
US20210338465A1 (en) * | 2014-07-20 | 2021-11-04 | Restore Medical Ltd. | Pulmonary artery implant apparatus and methods of use thereof |
US11717425B2 (en) * | 2014-07-20 | 2023-08-08 | Restore Medical Ltd. | Pulmonary artery implant apparatus and methods of use thereof |
US20170172771A1 (en) * | 2014-07-20 | 2017-06-22 | Elchanan Bruckheimer | Pulmonary artery implant apparatus and methods of use thereof |
US20200289299A1 (en) * | 2014-07-20 | 2020-09-17 | Restore Medical Ltd. | Pulmonary artery implant apparatus and methods of use thereof |
US10667931B2 (en) * | 2014-07-20 | 2020-06-02 | Restore Medical Ltd. | Pulmonary artery implant apparatus and methods of use thereof |
US10940296B2 (en) | 2015-05-07 | 2021-03-09 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Temporary interatrial shunts |
US11304831B2 (en) | 2016-05-31 | 2022-04-19 | V-Wave Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US11497631B2 (en) | 2016-05-31 | 2022-11-15 | V-Wave Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US11607327B2 (en) | 2016-05-31 | 2023-03-21 | V-Wave Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US11771434B2 (en) | 2016-09-28 | 2023-10-03 | Restore Medical Ltd. | Artery medical apparatus and methods of use thereof |
US11890017B2 (en) | 2016-09-28 | 2024-02-06 | Restore Medical Ltd. | Artery medical apparatus and methods of use thereof |
US11364132B2 (en) | 2017-06-05 | 2022-06-21 | Restore Medical Ltd. | Double walled fixed length stent like apparatus and methods of use thereof |
US11744589B2 (en) | 2018-01-20 | 2023-09-05 | V-Wave Ltd. | Devices and methods for providing passage between heart chambers |
US20220241565A1 (en) * | 2018-01-20 | 2022-08-04 | V-Wave Ltd | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same |
US11458287B2 (en) * | 2018-01-20 | 2022-10-04 | V-Wave Ltd. | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same |
CN112469368A (en) * | 2018-07-23 | 2021-03-09 | 美敦力公司 | Electrospun medical devices and methods of manufacturing electrospun medical devices |
WO2020023505A1 (en) * | 2018-07-23 | 2020-01-30 | Medtronic, Inc. | Electrospun medical devices and methods of making electrospun medical devices |
CN113329717A (en) * | 2018-11-29 | 2021-08-31 | V-波有限责任公司 | System and method for making a packaged hourglass-shaped stent |
JP2022518470A (en) * | 2019-01-29 | 2022-03-15 | ゼルティス アーゲー | Electrospinning cover layer for medical implants |
WO2020156711A1 (en) * | 2019-01-29 | 2020-08-06 | Xeltis Ag | Electrospun cover layer for medical implants |
WO2020260661A1 (en) * | 2019-06-27 | 2020-12-30 | Xeltis Ag | Electrospun heart valves |
US11160961B2 (en) | 2019-09-09 | 2021-11-02 | Shifamed Holdings, Llc | Adjustable shunts and associated systems and methods |
US11253685B2 (en) | 2019-12-05 | 2022-02-22 | Shifamed Holdings, Llc | Implantable shunt systems and methods |
US11622695B1 (en) | 2020-04-23 | 2023-04-11 | Shifamed Holdings, Llc | Intracardiac sensors with switchable configurations and associated systems and methods |
WO2021231182A1 (en) * | 2020-05-10 | 2021-11-18 | Vitae LLC | Balloon-expandable heart valve system and method of implantation |
US11801369B2 (en) | 2020-08-25 | 2023-10-31 | Shifamed Holdings, Llc | Adjustable interatrial shunts and associated systems and methods |
US11633194B2 (en) | 2020-11-12 | 2023-04-25 | Shifamed Holdings, Llc | Adjustable implantable devices and associated methods |
US11857197B2 (en) | 2020-11-12 | 2024-01-02 | Shifamed Holdings, Llc | Adjustable implantable devices and associated methods |
US11234702B1 (en) | 2020-11-13 | 2022-02-01 | V-Wave Ltd. | Interatrial shunt having physiologic sensor |
US20220371259A1 (en) * | 2021-05-18 | 2022-11-24 | Bcm Co., Ltd. | Method of manufacturing covered stent and covered stent manufactured thereby |
US11813386B2 (en) | 2022-04-14 | 2023-11-14 | V-Wave Ltd. | Interatrial shunt with expanded neck region |
Also Published As
Publication number | Publication date |
---|---|
US20200078196A1 (en) | 2020-03-12 |
US20210393421A1 (en) | 2021-12-23 |
US11109988B2 (en) | 2021-09-07 |
US11497631B2 (en) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11497631B2 (en) | Systems and methods for making encapsulated hourglass shaped stents | |
US11607327B2 (en) | Systems and methods for making encapsulated hourglass shaped stents | |
AU2019202647B2 (en) | Renal pump | |
US11690976B2 (en) | Apparatus and methods for delivering devices for reducing left atrial pressure | |
EP3886761A1 (en) | Systems and methods for making encapsulated hourglass shaped stents | |
US20210338990A1 (en) | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same | |
US10912920B2 (en) | Self-expanding cannula | |
WO2020217194A1 (en) | Interatrial shunts having biodegradable material, and methods of making and using same | |
US11813386B2 (en) | Interatrial shunt with expanded neck region | |
US20230191093A1 (en) | Devices with dimensions that can be reduced and increased in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |